Next Article in Journal / Special Issue
Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
Previous Article in Journal
Genetic Diversity and Phylodynamics of Avian Coronaviruses in Egyptian Wild Birds
Previous Article in Special Issue
Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

From SARS to MERS, Thrusting Coronaviruses into the Spotlight

1
Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) & Comparative Medicine Centre, Peking Union Medical Collage (PUMC), Beijing 100021, China
2
NHC Key Laboratory of Human Disease Comparative Medicine, the Institute of Laboratory Animal Sciences, CAMS&PUMC, Beijing 100021, China
3
Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious, Beijing 100021, China
*
Author to whom correspondence should be addressed.
Submission received: 16 December 2018 / Revised: 3 January 2019 / Accepted: 9 January 2019 / Published: 14 January 2019
(This article belongs to the Special Issue MERS-CoV)

Abstract

:
Coronaviruses (CoVs) have formerly been regarded as relatively harmless respiratory pathogens to humans. However, two outbreaks of severe respiratory tract infection, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), as a result of zoonotic CoVs crossing the species barrier, caused high pathogenicity and mortality rates in human populations. This brought CoVs global attention and highlighted the importance of controlling infectious pathogens at international borders. In this review, we focus on our current understanding of the epidemiology, pathogenesis, prevention, and treatment of SARS-CoV and MERS-CoV, as well as provides details on the pivotal structure and function of the spike proteins (S proteins) on the surface of each of these viruses. For building up more suitable animal models, we compare the current animal models recapitulating pathogenesis and summarize the potential role of host receptors contributing to diverse host affinity in various species. We outline the research still needed to fully elucidate the pathogenic mechanism of these viruses, to construct reproducible animal models, and ultimately develop countermeasures to conquer not only SARS-CoV and MERS-CoV, but also these emerging coronaviral diseases.

1. Introduction

Before the first outbreak of severe acute respiratory syndrome (SARS), a limited number of coronaviruses were known to be circulating in humans, causing only mild illnesses, such as the common cold [1]. Following the 2003 SARS pandemic [2,3], it became apparent that coronaviruses could cross the species barrier and cause life-threatening infections in humans. Therefore, further attention needs to be paid to these new coronaviruses.
The 21st century has seen the worldwide spread of two previously unrecognized coronaviruses, the severe acute respiratory syndrome coronavirus (SARS-CoV) [4] and Middle East respiratory syndrome coronavirus (MERS-CoV), both of which are highly pathogenic. Starting from November 2002 in China [5], there have been unprecedented nosocomial transmissions from person to person of SARS-CoV, accompanied by high fatality rates. A united global effort led to the rapid identification of the SARS coronavirus and remarkable scientific advancements in epidemic prevention. Additionally, the zoonotic transmission of SARS from December 2003 to January 2004 [6] provided insight for researchers into the origin of this novel coronavirus. Notably, the SARS pandemic was declared to be over in 2004 when no more infections in patients were being detected. Subsequently, certain SARS-CoV-like viruses found in bats demonstrated the ability to infect human cells without prior adaptation [7,8] which indicates the possibility of the re-emergence of SARS-CoV or SARS-CoV-like viruses.
A decade later in June 2012, another highly pathogenic and novel coronavirus, MERS-CoV, was isolated from the sputum of a male patient who died from acute pneumonia and renal failure in Saudi Arabia [9]. Nosocomial infections were reported, and international travel led to the transmission of MERS-CoV to countries outside of the Arabian Peninsula, causing it to become a global pathophoresis. In May 2015, an outbreak of MERS occurred in South Korea due to an individual returning from the Middle East [10]. Based on the lessons learned from managing SARS-CoV prevalence over the last decade, tremendous progress toward unraveling the biological characteristics of MERS-CoV has been achieved at an unprecedented speed. Scientific advancements have allowed for rapid and systemic progress in our understanding of the epidemiology and pathogenesis of MERS-CoV.
SARS-CoV and MERS-CoV share several important common features that contribute to nosocomial transmission, preferential viral replication in the lower respiratory tract, and viral immunopathology. This review highlights the epidemiology and pathogenesis of these viruses, including our current understanding of their biological characteristics, their transmission, and their replication in the host. The spike proteins (S proteins) of CoVs play pivotal roles in viral infection and pathogenesis. As critical surface-located trimeric glycoproteins of CoVs, they guide entry into host cells. In this review, we summarize the structure and function of the S proteins and therapeutics designed to target them. Moreover, we will explore how CoV–host interactions cause pathogenic outcomes and discuss potential treatment options, as well as describe recent mammalian models that closely recapitulate the pathogenic process and have contributed to the development of prevention and treatment strategies for SARS-CoV and MERS-CoV. Although several potential therapies have been identified with SARS and MERS in animal and in vitro models, human clinical trials remain lacking, hindering the advancement of these potential countermeasures.

2. Epidemiology of SARS-CoV and MERS-CoV

Prior to the outbreaks of SARS and MERS [2,9], the clinical importance and epidemic possibility of CoVs had been recognized by researchers, (Table 1). In 2002, a SARS epidemic that originated in Guangdong Province in China resulted in 916 deaths among more than 8098 patients in 29 countries [11], identifying SARS as the first new infectious disease of the 21st century. Ten years later, the World Health Organization (WHO) published 2254 laboratory-confirmed cases of MERS-CoV that occurred from 2012 to 16 September 2018, with at least 800 deaths in 27 countries. Remarkably, more than 80% of recent research into the virology and genetics of this infection indicated that bats could be the possible natural reservoirs of both SARS and MERS-CoV. Palm civets [12] and dromedary camels [13] are also possible intermediary hosts of SARS and MERS, respectively, before dissemination to humans [14].
The transmission mechanism of SARS-CoV and MERS-CoV has yet to be fully understood. For transmission from animals to humans, direct contact with the intermediary host might be one route. Recent reports demonstrated that camel workers in Saudi Arabia with high prevalence of MERS-CoV infection may contribute to the transmission of MERS [15]. Some customs and habits may also be conducive to transmission, such as the consumption of milk, urine, or uncooked meat. In this way, MERS-CoV was transmitted from dromedary camels directly to humans, principally in the Arabian Peninsula, and this is considered to be the main route of transmission from animals to humans, causing significant morbidity and mortality [16,17]. Human-to-human spread has also been detected, especially through nosocomial transmission. Delays in diagnosis in hospitals might lead to secondary cases among healthcare workers, family members, or other patients sharing rooms [18,19,20,21,22]. Among the reported cases of SARS, 22% were healthcare workers in China and more than 40% were healthcare workers in Canada [23]. Nosocomial transmission for MERS has similarly been seen in the Middle East [16] and in the Republic of Korea [22]. Outbreaks in other countries all resulted from the reported cases in the Middle East or North Africa, and transmission was the result of international travel. Both SARS and MERS caused large outbreaks with significant public health and economic consequences.

3. Pathogenesis of SARS-CoV and MERS-CoV

Although our current understanding of the pathogenesis of the SARS-CoV and MERS-CoV infection remains unclear, we summarize what is presently known (Table 2).
Coronaviruses are the largest kind of positive-strand RNA viruses (26–32 kb) as they are about 125 nm in diameter [24], and comprise four genera (alpha-, beta-, gamma-, and delta-coronavirus) [25]. Currently, six human CoVs (HCoVs) have been confirmed: HCoV-NL63 and HCoV-229E, which belong to the alpha-coronavirus genus; and HCoV-OC43, HCoV-HKU1, SARS-CoV, and MERS-CoV, which belong to the beta-coronavirus genus. SARS-CoV and MERS-CoV are the two major causes of severe pneumonia in humans and share some common coronavirus structural characteristics. Similarly, their genomic organization is typical of coronaviruses, having an enveloped, single, positive-stranded RNA genome that encodes four major viral structural proteins, namely spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins 3–5, that follow the characteristic gene order [5′-replicase (rep gene), spike (S), envelope (E), membrane (M), nucleocapsid (N)-3′] with short untranslated regions at both termini (Figure 1). The viral membrane contains S, E, and M proteins, and the spike protein plays a vital functional role in viral entry. The rep gene encodes the non-structural protein and constitutes approximately two-thirds of the genome at the 5′ end. In detail, the S protein is in charge of receptor-binding and subsequent viral entry into host cells, and is therefore a major therapeutic target [26,27]. The M and E proteins play important roles in viral assembly, and the N protein is necessary for RNA synthesis.
The SARS-CoV genome has 29,727 nucleotides in length, including 11 open reading frames (ORFs). The SARS-CoV rep gene, containing about two-thirds of the genome, encodes at least two polyproteins (encoded by ORF1a and ORF1b) that undergo the process of cotranslational proteolysis. Between ORF1b and S of group 2 and some group 3 coronaviruses, there is a gene that encodes hemagglutinin-esterase [4], while this was not detected in SARS-CoV. This virus is significantly different from previously reported coronaviruses for many reasons, such as the short anchor of the S protein, the specific number and location of small ORFs, and the presence of only one copy of PLPpro.
The MERS-CoV genome is larger than that of SARS-CoV at 30,119 nucleotides in length, and comprises a 5′ terminal cap structure, along with a poly (A) tail at the 3′ end, as well as the rep gene containing 16 non-structural proteins (nsp1–16) at the 5′ end of the genome. Four structural proteins (S, E, M, and N) and five accessory proteins (ORF3, ORF4a, ORF4b, ORF5, and ORF8) constitute about 10 kb at the 3′ end of the genome. Unlike some other beta-coronaviruses, the MERS-CoV genome does not encode a hemagglutinin-esterase (HE) protein [1]. Genomic analysis of MERS-CoV implies the potential for genetic recombination during a MERS-CoV outbreak [9]. MERS-CoV and SARS-CoV possess five and eight accessory proteins, respectively, which might help the virus evade the immune system by being harmful to the innate immune response. These differences might lead to greater sensitivity to the effects of induction and signaling of type 1 interferons (IFNs) in MERS-CoV than SARS-CoV.

4. Comparative Pathology and Life Cycles of SARS-CoV and MERS-CoV

Both SARS and MERS cause severe pneumonia resulting from these novel coronaviruses, sharing some similarities in their pathogenesis (Figure 2) [28].
SARS is an emerging infectious viral disease characterized by severe clinical manifestations of the lower respiratory tract, resulting in diffuse alveolar damage. SARS-CoV spreads through respiratory secretions, such as droplets, via direct person-to-person contact. Upon exposure of the host to the virus, the virus binds to cells expressing the virus receptors, of which the angiotensin-converting enzyme 2 (ACE2) is one of the main receptors, and CD209L is an alternative receptor with a much lower affinity [29]. In the respiratory tract, ACE2 is widely expressed on the epithelial cells of alveoli, trachea, bronchi, bronchial serous glands [30], and alveolar monocytes and macrophages [31]. The virus enters and replicates in these target cells. The mature virions are then released from primary cells and infect new target cells [32]. Furthermore, as a surface molecule, ACE2 is also diffusely localized on the endothelial cells of arteries and veins, the mucosal cells of the intestines, tubular epithelial cells of the kidneys, epithelial cells of the renal tubules, and cerebral neurons and immune cells, providing a variety of susceptible cells to SARS-CoV [33,34]. Respiratory secretions, urine, stools, and sweat from patients with SARS contain infective viral particles, which may be excreted into and contaminate the environment. Atypical pneumonia with rapid respiratory deterioration and failure can be induced by SARS-CoV infection because of increased levels of activated proinflammatory chemokines and cytokines [35].
For MERS-CoV infection of humans, the primary receptor is a multifunctional cell surface protein, dipeptidyl peptidase 4 (DPP4, also known as CD26) [36], which is widely expressed on epithelial cells in the kidney, alveoli, small intestine, liver, and prostate, and on activated leukocytes [37]. Consistent with this, MERS-CoV can infect several human cell lines, including lower respiratory, kidney, intestinal, and liver cells, as well as histiocytes, as shown by a cell-line susceptibility study [38], indicating that the range of MERS-CoV tissue tropism in vitro was broader than that of any other CoV. MERS-CoV causes acute, highly lethal pneumonia and renal dysfunction with various clinical symptoms, including—but not restricted to—fever, cough, sore throat, myalgia, chest pain, diarrhea, vomiting, and abdominal pain [39,40]. Lung infection in the MERS animal model demonstrated infiltration of neutrophils and macrophages and alveolar edema [41]. The entry receptor (DPP4) for MERS-CoV is also highly expressed in the kidney, causing renal dysfunctions by either hypoxic damage or direct infection of the epithelia [42]. Remarkably, unlike SARS-CoV, MERS-CoV has the ability to infect human dendritic cells [43] and macrophages [44] in vitro, thus helping the virus to disrupt the immune system. T cells are another target for MERS-CoV because of their high amounts of CD26 [45]. This virus might deregulate antiviral T-cell responses due to the stimulation of T-cell apoptosis [45,46]. MERS-CoV might also lead to immune dysregulation [47] by stimulating attenuated innate immune responses, with delayed proinflammatory cytokine induction in vitro and in vivo [44,48,49].

5. SARS and MERS-CoV Spike Protein: A Key Target for Antivirals

5.1. Structure of the SARS-CoV and MERS-CoV Spike Protein

Trimers of the S protein make up the spikes of SARS-CoV and provide the formation of a 1255-amino-acids-length surface glycoprotein precursor. Most of the protein and the amino terminus are situated on the outside of the virus particle or the cell surface [50]. The expected structure of the S protein comprises four parts: a signal peptide located at the N terminus from amino acids 1 to 12, an extracellular domain from amino acids 13 to 1195, a transmembrane domain from amino acids 1196 to 1215, and an intracellular domain from amino acids 1216 to 1255. Proteases such as factor Xa, trypsin, and cathepsin L cleave the SARS-CoV S protein into two subunits, the S1 and S2 subunits. A minimal receptor-binding domain (RBD) located in the S1 subunit (amino acids 318–510) can combine with the host cell receptor, ACE2. The RBD displays a concave surface during interaction with the receptor. The entire receptor-binding loop, known as the receptor-binding motif (RBM) (amino acids 424–494), is located on the RBD and is responsible for complete contact with ACE2. Importantly, two residues in the RBM at positions 479 and 487 determine the progression of the SARS disease and the tropism of SARS-CoV [51,52]. Recent studies using civets, mice, and rats demonstrated that any change in these two residues might improve animal-to-human or human-to-human transmission and facilitate efficient cross-species infection [53]. The S2 subunit mediates the fusion between SARS-CoV and target cells, and includes the heptad repeat 1 (HR1) and HR2 domains, whose HR1 region is longer than the HR2 region.
Similar to SARS-CoV, during the infection process, the S protein of MERS-CoV is cleaved into a receptor-binding subunit S1 and a membrane-fusion subunit S2 [54,55,56,57]. The MERS-CoV S1 subunit also includes an RBD, mediating the attachment between virus and target cells [54,55,58,59]. Unlike SARS-CoV, MERS-CoV requires DPP4 (also known as CD26) as its cellular receptor [60,61] but not ACE2. The RBDs of MERS-CoV and SARS-CoV differ, although they share a high degree of structural similarity in their core subdomains, explaining the different critical receptors noted above [57,62]. The core subdomain of RBD is stabilized by three disulfide bonds, and includes a five-stranded antiparallel β-sheet and several connecting helices. The RBM comprises a four-stranded antiparallel β-sheet for connecting to the core via loops [57,62]. Two N-linked glycans, N410 and N487, are seated in the core and RBM, respectively. Particularly, the residues 484–567 of RBM take charge of interacting with the extracellular β-propeller domain of DPP4. The fusion core formation of MERS-CoV resembles that of SARS-CoV; however, it is different from that of other coronaviruses, such as the mouse hepatitis virus (MHV) and HCoV-NL63 [63,64,65,66].

5.2. Functions of the SARS-CoV and MERS-CoV S Protein

The SARS-CoV S protein plays pivotal roles in viral infection and pathogenesis [67,68]. The S1 subunit recognizes and binds to host receptors, and the subsequent conformational changes in the S2 subunit mediate fusion between the viral envelope and the host cell membrane [69,70]. The RBD in the S1 subunit is responsible for virus binding to host cell receptors [61,70,71]. ACE2 is a functional receptor for SARS-CoV that makes contact with 14 amino acids in the RBD of SARS-CoV among its 18 residues [53]. The RBD in the S1 subunit is responsible for virus binding to host cell receptors [61,70,71]. Position R453 in the RBD and position K341 in ACE2 play indispensable roles in complex formation [72]. Furthermore, the N479 and T487 in the RBD of the S protein are pivotal positions for the affinity with ACE2 [52], and R441 or D454 in the RBD influences the antigenic structure and binding activity between RBD and ACE2 [73]. From a pre-fusion structure to a post-fusion structure, binding of the RBD in the S1 subunit to the receptor ACE2 stimulates a conformational change in S2. Accordingly, the supposed fusion peptide (amino acids 770–788) [74] builds in the target cell membrane of the host. Meanwhile, a six-helix bundle fusion core structure is made up by the HR1 and HR2 domains for bringing the viral envelope and the target cell membrane into close proximity and contributing to fusion [74]. Resembling the S2 subunit of SARS-CoV, the MERS-CoV S2 subunit is in charge of membrane fusion. The HR1 and HR2 regions in S2 play essential and complementary roles [56,63]. Furthermore, SARS-CoV displays an alternative method of binding to the host cell via other potential receptors. Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and/or liver/lymph node-SIGN (L-SIGN) are two examples of such receptors [29,75]. Seven residue sites, at positions 109, 118, 119, 158, 227, 589, and 699 of the S protein displaying asparagine-linked glycosylation are crucial for DC-SIGN or L-SIGN-mediated virus entry. These residues, unlike those of the ACE2-binding domain, function independently of ACE2 [76].

5.3. Vaccines Based on the SARS-CoV and MERS-CoV S Protein

In order to control the outbreak of viruses, vaccinations were developed against SARS-CoV and MERS-CoV. There are various approaches of different vaccines, and the development and advantages/disadvantages of these are listed in Table 3 (this table includes updates about SARS-CoV and MERS-CoV since 2013; SARS-CoV-related parts were modified by Graham et al. in Nature Reviews Microbiology, 2013 [77]).
Importantly, among all the functional/non-functional structural proteins of SARS-CoV and MERS-CoV, the S protein is the principal antigenic component that induces antibodies to block virus-binding, stimulate host immune responses, fuse or neutralize antibodies and/or protect the immune system against virus infection. Therefore, the S protein has been selected as a significant target for the development of vaccines. It has been noted that antibodies raised against subunit S1 (amino acids 485–625) or S2 (amino acids 1029–1192) neutralize infection by SARS-CoV strains in Vero E6 cells [78,79]. Researchers have constructed an attenuated parainfluenza virus encoding the full-length S protein of the SARS-CoV Urbani strain for the vaccination of African green monkeys. This vaccine could protect monkeys from subsequent homologous SARS-CoV infection, demonstrating highly effective immunization with the S protein [80]. Other studies in a mouse model structured a DNA vaccine encoding the full-length S protein of the SARS-CoV Urbani strain that not only induced T-cell and neutralizing-antibody responses, but also stimulated protective immunity [81]. Furthermore, monkeys or mice were vaccinated with a highly attenuated, modified vaccine virus, Ankara, encoding the full-length S protein of the SARS-CoV strain HKU39849 or Urbani [82]. However, full-length S protein-based SARS vaccines may induce harmful immune responses, causing liver damage in the vaccinated animals or enhancing infection after being challenged with homologous SARS-CoV [83,84]. Researchers are thus concerned about the safety and ultimate protective efficacy of vaccines that include the full-length SARS-CoV S protein.
There are still no commercial vaccines available against MERS-CoV [26]. Multiple vaccine candidates targeting the S protein, which is responsible for viral entry, have been developed, including subunit vaccines [85,86], recombinant vector vaccines [87,88], and DNA vaccines [89,90]. Importantly, compared with other regions of the S protein, the RBD fragment induced the highest-titer IgG antibodies in mice [85]. Modified vaccines, including recombinant vectors of Ankara and adenoviruses expressing the MERS-CoV S glycoprotein, showed immunogenicity in mice [25]. Attenuated live vaccines also showed a protective function, but there were concerns regarding the degree of attenuation [91]. After intranasal vaccination with the CoV N protein, airway memory CD4 T cells were generated and mediated the protection following a CoV challenge [92]. These cells could induce anti-viral innate responses at an early stage of infection, and facilitated CD8 T-cell responses by stimulating recombinant dendritic cell migration and CD8 T-cell mobilization [92]. The stimulation of airway memory CD4 T cells should be regarded as an essential part of any HCoV vaccine strategy, because these CD4 T cells target a conserved epitope within the N protein that cross-reacts with several other CoVs [92]. Furthermore, DNA vaccines expressing the MERS-CoV S1 gene produced antigen-specific humoral and cellular immune responses in mice [89].

5.4. S Protein-Based Therapeutics for SARS-CoV and MERS-CoV

Despite the presence of extensive research reporting on SARS-CoV and MERS-CoV therapies, it was not possible to establish whether treatments benefited patients during their outbreak. In the absence of fundamental, clinically proven, effective antiviral therapy against SARS-CoV and MERS-CoV, patients mainly receive supportive care supplemented by diverse combinations of drugs. Several approaches are being considered to treat infections of SARS-CoV [113] and MERS-CoV (Table 4, MERS-CoV-related table previously reviewed by de Wit et al. in Nature Reviews Microbiology, 2016 [10]), including the use of antibodies, IFNs, and inhibitors of viral and host proteases.
The vital role of the S protein of SARS-CoV makes this protein an important therapeutic target, and numerous studies have explored potential therapeutics. Firstly, peptides that block RBD–ACE2-binding derived from both RBD [114] and ACE2 [76] could be developed as novel therapeutics against SARS-CoV infection. Secondly, peptides binding to the S protein interfere with the cleavage of S1 and S2. This step inhibits the production of functional S1 and S2 subunits and the consequent fusion of the viral envelope with the host cell membrane. Thirdly, anti-SARS-CoV peptides blocking the HR1–HR2 interaction by forming a fusion-active core have viral fusion inhibitory activity at the micromolar level [115,116,117]. However, the potential selection of escape mutants with altered host range phenotypes is one of the disadvantages of this strategy that needs further modification [118]. Furthermore, mouse monoclonal antibodies (mAbs) targeting assorted fragments of the SARS-CoV S protein have effectively inhibited SARS-CoV infection [79,119,120,121,122]. A series of neutralizing human mAbs were generated from the B cells of patients infected with SARS-CoV [123,124]. Another strategy used human immunoglobulin transgenic mice immunized with full-length SARS-CoV S proteins [125,126,127]. 80R and CR3014 binding to the ACE2 receptor are examples of S-specific mAbs [128,129].
Similarly, the therapeutic agents that have been developed against MERS-CoV are based on the S protein and basically restrain the binding of receptors or the fusion of membrane proteins, thereby leading to the inhibition of MERS-CoV infection. These methods mainly involve peptidic fusion inhibitors [56,63,116,130], anti-MERS-CoV neutralizing mAbs [86,131], anti-DPP4 mAbs [86,132,133], DPP4 antagonists [134], and protease inhibitors [135,136,137]. However, none of these anti-MERS-CoV curative agents are approved for commercial use in humans.

6. The Animal Models of SARS and MERS-CoV

International coordination and cooperation led to the rapid identification of SARS-CoV and MERS-CoV. Emergency control measures and laboratory detection systems which were put in place in response to SARS-CoV and MERS-CoV outbreaks were both exemplary. To establish optimal prevention and control strategies for SARS and MERS, numerous efforts to develop animal models were undertaken in several laboratories, despite the fact that some conflicting results have been reported. It is therefore necessary to compare and document the features and disadvantages of different animal models to better understand viral replication, transmission, pathogenesis, prevention, and treatment. Notably, several animal species were suggested as suitable disease models of SARS-CoV, but most laboratory animals are refractory or only semi-permissive to MERS-CoV infection.

6.1. Animal Models of SARS-CoV

SARS-CoV replication has been studied in mice, Syrian golden and Chinese hamsters, civet cats, and non-human primates. The most severe symptoms of SARS were observed in aged animals. To develop epidemiological symptoms that advanced age resulted in increased mortality, aged mouse model of SARS-CoV has been generated. Transgenic mice expressing human ACE2 were also developed to closely mimic SARS-CoV infection in humans. Some animal models have been tested and analyzed on the genomic and proteomics level to study the pathogenesis of SARS.

6.1.1. Mouse Models

Mouse species that have been used as SARS-CoV-infected animal models include BALB/c [149,150], C57BL6 (B6) [151], and 129SvEv-lineage mice. The most relevant transgenic and knockout lines are accessible based on these susceptible animals [152]. Signal transducers and activators of transcription 1 (STAT1)-knockout and myeloid differentiation primary response 88 (MYD88)-knockout mice [149,151,153,154] are examples of mouse models with innate immune deficiency, and such animals display severe effects of the disease, such as pneumonitis, bronchiolitis, and weight loss, and often die within 9 days of infection. Notably, young mice require more mutations and passages than aged mice to produce SARS-CoV mouse-adapted strains. More severe pathological lesions and increased mortality were observed in one-year-old animals, along with fewer mutations at miscellaneous locations throughout the genome [98,155,156,157,158,159]. Intranasal inoculation of four- to eight-week-old BALB/c or B6 mice with SARS-CoV resulted in nasal turbinate in the upper respiratory tract and a high titer of virus replication in the lungs of the lower respiratory tract, and this model was highly reproducible without any signs of morbidity or mortality [149,151]. Neutralizing antibody responses could be generated in sub-lethally infected mice protecting recipients from subsequent lethal challenges, which probably reflected the situation in infected humans during an epidemic [160]. However, on day 2–3 post-infection (pi), virus replication in the respiratory tract peaked but was not accompanied by massive pulmonary inflammation or pneumonitis. By day 5–7 pi, the virus had been eliminated from the lungs [149,151]. It was obvious that viremia is common and long-lasting in patients, while it is rare and transient in mouse models [161]. Mice could therefore be used as a stable and reproducible animal model for the evaluation of vaccines, immune-prophylaxis, and antiviral drugs against SARS-CoV [81,96,109,124,149,162,163,164,165,166].

6.1.2. Hamster Model

Golden Syrian and Chinese hamsters have also been evaluated and shown to be excellent models of SARS-CoV infection, owing to their high titer of virus replication in the respiratory tract, associated with diffuse alveolar damage, interstitial pneumonitis, and pulmonary consolidation [104,167,168,169]. On day 2 pi, peak levels of viral replication were detected in the lower respiratory tract, and the virus was cleared without obvious clinical illness 7–10 days after infection. Similarly to mice, infected hamsters also produced a protective neutralizing-antibody response to subsequent SARS-CoV challenges [104,170]. Resulting from the extremely high titers and reproducible pulmonary pathological lesions in SARS-CoV-infected hamsters, this animal model is ideal for studies on the immunoprophylaxis and treatment of SARS [104,170]. However, there are still limited resources in terms of genetically established animal lines and accurate immunological and cellular biomarkers for hamster models.

6.1.3. Ferret Model

Ferrets were found to be susceptible to SARS-CoV infection [171] but could also transmit the virus at low levels by direct contact [84,172,173,174]. They showed diverse clinical symptoms in different studies [171,174]. Importantly, ferrets could develop fever, which is a characteristic clinical symptom of SARS-CoV-infected patients [93,175]. Similar to rodent models, infection of ferrets with SARS-CoV did not result in significant mortality. However, there are still some conflicting reports regarding the histopathological lesions and severity of clinical observations in the ferret model that require further investigation.

6.1.4. Non-Human Primate Models

Several species of non-human primates (NHP) were evaluated as animal models for SARS. At least six NHP species were tested including three Old World monkeys: rhesus macaques [176,177,178,179,180], cynomolgus macaques [177,181,182], and African green monkeys [177]; and three New World monkeys: the common marmoset [183], squirrel monkeys, and mustached tamarins [176,177,178,181,182,183,184]. Except for squirrel monkeys and mustached tamarins [185], all of the evaluated NHP species facilitated the replication of SARS-CoV [186]. Virus replication was detected in the respiratory tract of rhesus macaques, cynomolgus macaques, and African green monkeys. Pneumonitis was observed in each of these species in different studies [176,177,178,182]. SARS-infected common marmosets displayed a fever, watery diarrhea, pneumonitis, and hepatitis [183]. Unfortunately, research into the clinical signs of disease in cynomolgus and rhesus macaques gave conflicting results and therefore needs further investigation. The main reason for the lack of reproducibility in such studies may be the limited sample size.

6.2. Animal Models of MERS-CoV

Small animal models of MERS infection are urgently needed to elucidate MERS pathogenesis and explore potential vaccines and antiviral drugs. Previous studies have demonstrated the difficulties in developing such a model, such as that mice [187,188], ferrets [134], guinea pigs [189], and hamsters [189] are not susceptible to experimental MERS-CoV infection mainly because their homologous DPP4 molecules do not function as receptors for MERS-CoV entry. After administering a high dose of MERS-CoV, no viral replication could be detected in these animals [190]. In an animal model using New Zealand white rabbits, regardless of the fact that detectable viral RNA existed in the respiratory tract and moderate necrosis was observed in nasal turbinates, the animals showed no clinical symptoms of disease [191]. In another study, attempts to infect hamsters with MERS-CoV were not successful [192]. However, despite this, MERS-CoV is a broad host-range virus in vitro [25], and there is hope that a reproducible and stable animal model for human MERS-CoV infection can be improved in the near future.

6.2.1. Mouse Model for MERS Infection

Despite the fact that wild-type rodents are not susceptible to MERS-CoV infection [188], researchers have developed several models in which mice are susceptible to MERS-CoV infection [193,194,195]. The first mouse model of MERS infection reported in 2014 involved transducing animals with recombinant adenovirus 5 encoding human DPP4 (hDPP4) molecules intranasally, and this resulted in replication of MERS-CoV in the lungs. This mouse model also showed clinical symptoms of interstitial pneumonia, including inflammatory cell infiltration, and thickened alveolar and mild edema [195]. However, there are certain limitations to this model, such as the uncontrolled expression and distribution of hDPP4. In 2015, the establishment of hDPP4 transgenic mice was reported [194]. MERS-CoV could infect this mouse model effectively. However, similarly to SARS-CoV-infected ACE2 transgenic mice [196], systemic expressions led to multiple organ lesions [194], resulting in the death of the animals. Most recently, the homologous hDPP4 gene was used in several MERS transgenic mouse models [193,197]. Remarkably, hDPP4 knockin (KI) mice, where mouse DPP4 gene fragments had been displaced by homologous human DPP4 fragments, showed effective receptor binding. Furthermore, a mouse-adapted MERS-CoV strain (MERSMA) including 13–22 mutations was produced in the lungs of hDPP4-KI mice after 30 serial passages, causing effective weight loss and mortality in this mouse model [193]. Both this hDPP4-KI mouse and the MERSMA strain provide better tools to explore the pathogenesis of MERS and potential novel treatments.

6.2.2. Camelidae

As a reservoir of MERS-CoV, dromedary camels showed mild upper respiratory infections after the administration of MERS-CoV [198]. Oronasal infection of MERS-CoV in alpacas, a close relative within the Camelidae family, resulted in an asymptomatic infection with no signs of upper or lower respiratory tract disease [199,200]. Additionally, owing to their high cost and relatively large size, these animal models are not available for high-throughput studies of MERS.

6.2.3. Non-Human Primates

NHPs, such as the rhesus macaques [201] and common marmosets [202], are useful models for studying the pathogenesis of mild MERS-CoV infection and evaluating novel therapies for humans, although the degree of replication and disease severity vary [192,201,203,204]. MERS-CoV caused transient lower respiratory tract infection in rhesus macaques, with associated pneumonia. Clinical signs were observed by day 1 pi and resolved as early as day 4 pi [201]. Relatively mild clinical symptoms were observed early on in infection without fatalities, indicating that rhesus macaques do not recapitulate the severe infections observed in human cases; however, treatment of MERS-CoV-infected rhesus macaques with IFN-α and ribavirin decreased virus replication, alleviated the host response, and improved the clinical outcome [205]. Infection of MERS-CoV in common marmosets demonstrated various extents of damage depending on the study, but successfully reproduced several features of MERS-CoV infection in humans. Importantly, one study indicated that the infection became progressive severe pneumonia [203], while other groups found that MERS-CoV-infected common marmosets only developed mild to moderate nonlethal respiratory diseases by intratracheal administration [206].

7. Role of Host Receptors in Animal Models of SARS-CoV and MERS-CoV

The reasons for host restriction, none or limited clinical symptoms observed in varies animal models are complexity. The interaction between the host receptor and functional proteins of SARS and MERS, respectively, plays an important and predominant role. In the context of animal models of SARS-CoV infection, researchers have compared the ACE2 amino acids that interact with the S protein RBD from several species. In agreement with the permissive nature of these species, the ACE2 residues of marmoset and hamster are similar to those of hACE2 [53]. By comparison, many residues of mouse ACE2 are different from those of hACE2, and this meets with decreased replication of SARS-CoV in mouse cells [207] and the lungs of young mice [149]. The changes at positions 353 (histidine) and 82 (asparagine) of rat ACE2 relative to hACE2 partially disrupt the S protein-DPP4 interaction and contribute to abrogation of binding. Interestingly, ferrets are permissive to SARS-CoV infection, but most of their ACE2 interaction residues are different from those of hACE2 [53], while many of the ACE2 residues between civet and ferret are the same, which may result in similar affinity [208]. For MERS-CoV, 14 residues of the S protein RBD have direct contact with 15 residues of hDPP4 [57]. Comparisons of human DPP4 binding affinity to that of other species indicated that human DPP4 had the highest affinity to the S protein of MERS-CoV, where the decreasing order of affinity is as follows: human > horses > camels > goats > bats [209]. Further evidence demonstrates that the host restriction of MERS-CoV remarkably depends on the sequence of DPP4, such as the characterization of amino acid residues at the connector of DPP4 with the RBD of S proteins in mice [187,210], hamsters, and cotton rats [210]. However, the multiplicity in severity of disease between rhesus macaques and common marmosets indicate that other host factors can perhaps affect the infection and replication of the virus, such as the presence of S-cleaving proteases [187]. In general, although the structural analysis of receptors-S protein interactions cannot fully explain all the observations for host restriction, they agree with the improved replication in several animal models and that it should be the premier and remarkable focus of small-animal model development. These special residues for host affinity are important to build up transgenic animal models enhancing the permissiveness and infection of SARS and MERS.

8. Outlook and Summary

Unlike SARS-CoV, which resolved without more reported cases, continued outbreaks of MERS-CoV present an ongoing threat to public health. It should be noted that no specific treatment is currently available for HCoVs, and further research into the pathogenesis of HCoV infection is therefore imperative to identify appropriate therapeutic targets. Accordingly, at present, the prevention of viral transmission is of utmost importance to limit the spread of MERS. The enormous ratio of nosocomial infections indicates that preventive measures in hospitals have not been sufficiently implemented. Additionally, as an emerging zoonotic virus, prevention of transmission from dromedary camels is another possibility to reduce the quantity of MERS cases. Regarding clinical therapies, a combination of treatment administered as early as possible and aimed at synchronously disrupting viral replication, inhibiting viral dissemination, and restraining the host response is likely to be most suitable, due to the acute clinical features of MERS with diffuse lung damage and the important role of immunopathology.
Potential treatments must undergo in vitro and in vivo studies to select the most promising options. The development of stable and reproducible animal models of MERS, especially in NHPs, is therefore a decisive step forward. The next step in the development of standardized and controllable therapies against SARS and MERS will be clinical trials in humans, validating a standard protocol for dosage and timing, and accruing data in real time during future outbreaks to monitor specific adverse effects and help inform treatment.
The comprehensive lessons and experiences that have resulted from the outbreaks of SARS and MERS provide valuable insight and advancements in how to react to future emerging and re-emerging infectious agents. Rapid identification of the pathogen via effective diagnostic assays is the first step, followed by the implementation of preventive measures, including raising awareness of the new agent, reporting and recording (suspected) cases, and infection control management in medical facilities. Studies are currently needed that focus on the epidemiology of these organisms, especially in terms of pathogen transmission and potential reservoirs and/or intermediate hosts. Animal models and prophylactic and therapeutic approaches should be promoted, followed by fast-tracked clinical trials.
Our increasing understanding of novel emerging coronaviruses will be accompanied by increasing opportunities for the reasonable design of therapeutics. Importantly, understanding this basic information will not only aid our public health preparedness against SARS-CoV and MERS-CoV, but also help prepare for novel coronaviruses that may emerge.

Funding

This research was funded by CAMS Innovation Fund for Medical Science (CIFMS), grant number 2016-12M-2-006.

Acknowledgments

We thank Kate Fox, DPhil, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Yin, Y.; Wunderink, R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018, 23, 130–137. [Google Scholar] [CrossRef] [PubMed]
  2. Drosten, C.; Gunther, S.; Preiser, W.; van der Werf, S.; Brodt, H.R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R.A.; et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1967–1976. [Google Scholar] [CrossRef] [PubMed]
  3. Ksiazek, T.G.; Erdman, D.; Goldsmith, C.S.; Zaki, S.R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J.A.; Lim, W.; et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1953–1966. [Google Scholar] [CrossRef] [PubMed]
  4. Rota, P.A. Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. Science 2003, 300, 1394–1399. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Zhong, N.S.; Zheng, B.J.; Li, Y.M.; Poon, L.L.; Xie, Z.H.; Chan, K.H.; Li, P.H.; Tan, S.Y.; Chang, Q.; Xie, J.P.; et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 2003, 362, 1353–1358. [Google Scholar] [CrossRef]
  6. Lee, N.; Hui, D.; Wu, A.; Chan, P.; Cameron, P.; Joynt, G.M.; Ahuja, A.; Yung, M.Y.; Leung, C.B.; To, K.F.; et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003, 348, 1986–1994. [Google Scholar] [CrossRef] [PubMed]
  7. Ge, X.Y.; Li, J.L.; Yang, X.L.; Chmura, A.A.; Zhu, G.; Epstein, J.H.; Mazet, J.K.; Hu, B.; Zhang, W.; Peng, C.; et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013, 503, 535–538. [Google Scholar] [CrossRef] [Green Version]
  8. Menachery, V.D.; Yount, B.J.; Debbink, K.; Agnihothram, S.; Gralinski, L.E.; Plante, J.A.; Graham, R.L.; Scobey, T.; Ge, X.Y.; Donaldson, E.F.; et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015, 21, 1508–1513. [Google Scholar] [CrossRef] [Green Version]
  9. Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367, 1814–1820. [Google Scholar] [CrossRef]
  10. de Wit, E.; van Doremalen, N.; Falzarano, D.; Munster, V.J. SARS and MERS: Recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016, 14, 523–534. [Google Scholar] [CrossRef]
  11. World Health Organization. WHO Guidelines for the Global Surveillance of Severe Acute Respiratory Syndrome (SARS). Updated Recommendations. October 2004. Available online: http://www.who.int/mediacentre/factsheets/mers-cov/en/ (accessed on 8 October 2018).
  12. Guan, Y.; Zheng, B.J.; He, Y.Q.; Liu, X.L.; Zhuang, Z.X.; Cheung, C.L.; Luo, S.W.; Li, P.H.; Zhang, L.J.; Guan, Y.J.; et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003, 302, 276–278. [Google Scholar] [CrossRef]
  13. Azhar, E.I.; El-Kafrawy, S.A.; Farraj, S.A.; Hassan, A.M.; Al-Saeed, M.S.; Hashem, A.M.; Madani, T.A. Evidence for camel-to-human transmission of MERS coronavirus. N. Engl. J. Med. 2014, 370, 2499–2505. [Google Scholar] [CrossRef] [PubMed]
  14. Cui, J.; Li, F.; Shi, Z. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2018. [Google Scholar] [CrossRef] [PubMed]
  15. Alshukairi, A.N.; Zheng, J.; Zhao, J.; Nehdi, A.; Baharoon, S.A.; Layqah, L.; Bokhari, A.; Al, J.S.; Samman, N.; Boudjelal, M.; et al. High Prevalence of MERS-CoV Infection in Camel Workers in Saudi Arabia. mBio 2018, 9, e01985-18. [Google Scholar] [CrossRef] [PubMed]
  16. Assiri, A.; Al-Tawfiq, J.A.; Al-Rabeeah, A.A.; Al-Rabiah, F.A.; Al-Hajjar, S.; Al-Barrak, A.; Flemban, H.; Al-Nassir, W.N.; Balkhy, H.H.; Al-Hakeem, R.F.; et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect. Dis. 2013, 13, 752–761. [Google Scholar] [CrossRef]
  17. Arabi, Y.M.; Arifi, A.A.; Balkhy, H.H.; Najm, H.; Aldawood, A.S.; Ghabashi, A.; Hawa, H.; Alothman, A.; Khaldi, A.; Al, R.B. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann. Intern. Med. 2014, 160, 389–397. [Google Scholar] [CrossRef] [PubMed]
  18. Al-Abdallat, M.M.; Payne, D.C.; Alqasrawi, S.; Rha, B.; Tohme, R.A.; Abedi, G.R.; Al, N.M.; Iblan, I.; Jarour, N.; Farag, N.H.; et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: A serologic, epidemiologic, and clinical description. Clin. Infect. Dis. 2014, 59, 1225–1233. [Google Scholar] [CrossRef] [PubMed]
  19. Al, H.F.; Pringle, K.; Al, M.M.; Kim, L.; Pham, H.; Alami, N.N.; Khudhair, A.; Hall, A.J.; Aden, B.; El, S.F.; et al. Response to Emergence of Middle East Respiratory Syndrome Coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014. Emerg. Infect. Dis. 2016, 22, 1162–1168. [Google Scholar] [Green Version]
  20. Assiri, A.; McGeer, A.; Perl, T.M.; Price, C.S.; Al, R.A.; Cummings, D.A.; Alabdullatif, Z.N.; Assad, M.; Almulhim, A.; Makhdoom, H.; et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 2013, 369, 407–416. [Google Scholar] [CrossRef]
  21. Drosten, C.; Muth, D.; Corman, V.M.; Hussain, R.; Al, M.M.; HajOmar, W.; Landt, O.; Assiri, A.; Eckerle, I.; Al, S.A.; et al. An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014. Clin. Infect. Dis. 2015, 60, 369–377. [Google Scholar] [CrossRef]
  22. Park, H.Y.; Lee, E.J.; Ryu, Y.W.; Kim, Y.; Kim, H.; Lee, H.; Yi, S.J. Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. Eurosurveillance 2015, 20, 21169. [Google Scholar] [CrossRef] [PubMed]
  23. Skowronski, D.M.; Astell, C.; Brunham, R.C.; Low, D.E.; Petric, M.; Roper, R.L.; Talbot, P.J.; Tam, T.; Babiuk, L. Severe acute respiratory syndrome (SARS): A year in review. Annu. Rev. Med. 2005, 56, 357–381. [Google Scholar] [CrossRef] [PubMed]
  24. Fehr, A.R.; Perlman, S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol. Biol. 2015, 1282, 1–23. [Google Scholar]
  25. Wang, Y.; Sun, J.; Zhu, A.; Zhao, J.; Zhao, J. Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models. J. Thorac. Dis. 2018, 10, S2260–S2271. [Google Scholar] [CrossRef] [PubMed]
  26. Du, L.; Yang, Y.; Zhou, Y.; Lu, L.; Li, F.; Jiang, S. MERS-CoV spike protein: A key target for antivirals. Expert Opin. Ther. Targets 2017, 21, 131–143. [Google Scholar] [CrossRef] [PubMed]
  27. Du, L.; He, Y.; Zhou, Y.; Liu, S.; Zheng, B.; Jiang, S. The spike protein of SARS-CoV—A target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009, 7, 226–236. [Google Scholar] [CrossRef]
  28. Zumla, A.; Hui, D.S.; Perlman, S. Middle East respiratory syndrome. Lancet 2015, 386, 995–1007. [Google Scholar] [CrossRef] [Green Version]
  29. Jeffers, S.A.; Tusell, S.M.; Gillim-Ross, L.; Hemmila, E.M.; Achenbach, J.E.; Babcock, G.J.; Thomas, W.J.; Thackray, L.B.; Young, M.D.; Mason, R.J.; et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 2004, 101, 15748–15753. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Liu, L.; Wei, Q.; Alvarez, X.; Wang, H.; Du, Y.; Zhu, H.; Jiang, H.; Zhou, J.; Lam, P.; Zhang, L.; et al. Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tracts of Rhesus Macaques. J. Virol. 2011, 85, 4025–4030. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Kuba, K.; Imai, Y.; Rao, S.; Gao, H.; Guo, F.; Guan, B.; Huan, Y.; Yang, P.; Zhang, Y.; Deng, W.; et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005, 11, 875–879. [Google Scholar] [CrossRef] [PubMed]
  32. Qinfen, Z.; Jinming, C.; Xiaojun, H.; Huanying, Z.; Jicheng, H.; Ling, F.; Kunpeng, L.; Jingqiang, Z. The life cycle of SARS coronavirus in Vero E6 cells. J. Med. Virol. 2004, 73, 332–337. [Google Scholar] [CrossRef] [PubMed]
  33. Guo, Y.; Korteweg, C.; McNutt, M.A.; Gu, J. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res. 2008, 133, 4–12. [Google Scholar] [CrossRef] [PubMed]
  34. Gu, J.; Korteweg, C. Pathology and pathogenesis of severe acute respiratory syndrome. Am. J. Pathol. 2007, 170, 1136–1147. [Google Scholar] [CrossRef] [PubMed]
  35. Ding, Y.; He, L.; Zhang, Q.; Huang, Z.; Che, X.; Hou, J.; Wang, H.; Shen, H.; Qiu, L.; Li, Z.; et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for pathogenesis and virus transmission pathways. J. Pathol. 2004, 203, 622–630. [Google Scholar] [CrossRef] [PubMed]
  36. Meyerholz, D.K.; Lambertz, A.M.; McCray, P.J. Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome. Am. J. Pathol. 2016, 186, 78–86. [Google Scholar] [CrossRef] [PubMed]
  37. Widagdo, W.; Raj, V.S.; Schipper, D.; Kolijn, K.; van Leenders, G.; Bosch, B.J.; Bensaid, A.; Segales, J.; Baumgartner, W.; Osterhaus, A.; et al. Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels. J. Virol. 2016, 90, 4838–4842. [Google Scholar] [CrossRef] [Green Version]
  38. Oboho, I.K.; Tomczyk, S.M.; Al-Asmari, A.M.; Banjar, A.A.; Al-Mugti, H.; Aloraini, M.S.; Alkhaldi, K.Z.; Almohammadi, E.L.; Alraddadi, B.M.; Gerber, S.I.; et al. 2014 MERS-CoV outbreak in Jeddah—A link to health care facilities. N. Engl. J. Med. 2015, 372, 846–854. [Google Scholar] [CrossRef]
  39. Chu, K.H.; Tsang, W.K.; Tang, C.S.; Lam, M.F.; Lai, F.M.; To, K.F.; Fung, K.S.; Tang, H.L.; Yan, W.W.; Chan, H.W.; et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int. 2005, 67, 698–705. [Google Scholar] [CrossRef] [Green Version]
  40. Saad, M.; Omrani, A.S.; Baig, K.; Bahloul, A.; Elzein, F.; Matin, M.A.; Selim, M.A.; Al, M.M.; Al, N.D.; Al, A.A.; et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: A single-center experience in Saudi Arabia. Int. J. Infect. Dis. 2014, 29, 301–306. [Google Scholar] [CrossRef]
  41. Alagaili, A.N.; Briese, T.; Mishra, N.; Kapoor, V.; Sameroff, S.C.; Burbelo, P.D.; de Wit, E.; Munster, V.J.; Hensley, L.E.; Zalmout, I.S.; et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio 2014, 5, e814–e884. [Google Scholar] [CrossRef]
  42. Lambeir, A.M.; Durinx, C.; Scharpe, S.; De Meester, I. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 2003, 40, 209–294. [Google Scholar] [CrossRef] [PubMed]
  43. Chu, H.; Zhou, J.; Wong, B.H.; Li, C.; Cheng, Z.S.; Lin, X.; Poon, V.K.; Sun, T.; Lau, C.C.; Chan, J.F.; et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology 2014, 454–455, 197–205. [Google Scholar] [CrossRef]
  44. Zhou, J.; Chu, H.; Li, C.; Wong, B.H.; Cheng, Z.S.; Poon, V.K.; Sun, T.; Lau, C.C.; Wong, K.K.; Chan, J.Y.; et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis. J. Infect. Dis. 2014, 209, 1331–1342. [Google Scholar] [CrossRef]
  45. Chu, H.; Zhou, J.; Wong, B.H.; Li, C.; Chan, J.F.; Cheng, Z.S.; Yang, D.; Wang, D.; Lee, A.C.; Li, C.; et al. Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways. J. Infect. Dis. 2016, 213, 904–914. [Google Scholar] [CrossRef]
  46. Yeung, M.; Yao, Y.; Jia, L.; Chan, J.F.W.; Chan, K.; Cheung, K.; Chen, H.; Poon, V.K.M.; Tsang, A.K.L.; To, K.K.W.; et al. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nat. Microbiol. 2016, 1, 16004. [Google Scholar] [CrossRef]
  47. Liu, W.J.; Lan, J.; Liu, K.; Deng, Y.; Yao, Y.; Wu, S.; Chen, H.; Bao, L.; Zhang, H.; Zhao, M.; et al. Protective T Cell Res.ponses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8+ T Cell Epitopes and Host MHC. J. Immunol. 2017, 198, 873–882. [Google Scholar] [CrossRef] [PubMed]
  48. Chan, R.W.; Chan, M.C.; Agnihothram, S.; Chan, L.L.; Kuok, D.I.; Fong, J.H.; Guan, Y.; Poon, L.L.; Baric, R.S.; Nicholls, J.M.; et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J. Virol. 2013, 87, 6604–6614. [Google Scholar] [CrossRef] [PubMed]
  49. Lau, S.K.; Lau, C.C.; Chan, K.H.; Li, C.P.; Chen, H.; Jin, D.Y.; Chan, J.F.; Woo, P.C.; Yuen, K.Y. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment. J. Gen. Virol. 2013, 94, 2679–2690. [Google Scholar] [CrossRef] [PubMed]
  50. Marra, M.A.; Jones, S.J.; Astell, C.R.; Holt, R.A.; Brooks-Wilson, A.; Butterfield, Y.S.; Khattra, J.; Asano, J.K.; Barber, S.A.; Chan, S.Y.; et al. The Genome sequence of the SARS-associated coronavirus. Science 2003, 300, 1399–1404. [Google Scholar] [CrossRef] [PubMed]
  51. Qu, X.X.; Hao, P.; Song, X.J.; Jiang, S.M.; Liu, Y.X.; Wang, P.G.; Rao, X.; Song, H.D.; Wang, S.Y.; Zuo, Y.; et al. Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. J. Biol. Chem. 2005, 280, 29588–29595. [Google Scholar] [CrossRef] [PubMed]
  52. Li, W.; Zhang, C.; Sui, J.; Kuhn, J.H.; Moore, M.J.; Luo, S.; Wong, S.K.; Huang, I.C.; Xu, K.; Vasilieva, N.; et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005, 24, 1634–1643. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Li, F.; Li, W.; Farzan, M.; Harrison, S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005, 309, 1864–1868. [Google Scholar] [CrossRef] [PubMed]
  54. Li, F. Receptor recognition mechanisms of coronaviruses: A decade of structural studies. J. Virol. 2015, 89, 1954–1964. [Google Scholar] [CrossRef] [PubMed]
  55. Lu, G.; Hu, Y.; Wang, Q.; Qi, J.; Gao, F.; Li, Y.; Zhang, Y.; Zhang, W.; Yuan, Y.; Bao, J.; et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013, 500, 227–231. [Google Scholar] [CrossRef] [PubMed]
  56. Gao, J.; Lu, G.; Qi, J.; Li, Y.; Wu, Y.; Deng, Y.; Geng, H.; Li, H.; Wang, Q.; Xiao, H.; et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J. Virol. 2013, 87, 13134–13140. [Google Scholar] [CrossRef]
  57. Wang, N.; Shi, X.; Jiang, L.; Zhang, S.; Wang, D.; Tong, P.; Guo, D.; Fu, L.; Cui, Y.; Liu, X.; et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013, 23, 986–993. [Google Scholar] [CrossRef] [Green Version]
  58. Zhang, N.; Jiang, S.; Du, L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev. Vaccines 2014, 13, 761–774. [Google Scholar] [CrossRef] [PubMed]
  59. Du, L.; Zhao, G.; Kou, Z.; Ma, C.; Sun, S.; Poon, V.K.; Lu, L.; Wang, L.; Debnath, A.K.; Zheng, B.J.; et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 2013, 87, 9939–9942. [Google Scholar] [CrossRef] [PubMed]
  60. Raj, V.S.; Mou, H.; Smits, S.L.; Dekkers, D.H.; Muller, M.A.; Dijkman, R.; Muth, D.; Demmers, J.A.; Zaki, A.; Fouchier, R.A.; et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495, 251–254. [Google Scholar] [CrossRef]
  61. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450–454. [Google Scholar] [CrossRef]
  62. Chen, Y.; Rajashankar, K.R.; Yang, Y.; Agnihothram, S.S.; Liu, C.; Lin, Y.L.; Baric, R.S.; Li, F. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J. Virol. 2013, 87, 10777–10783. [Google Scholar] [CrossRef]
  63. Lu, L.; Liu, Q.; Zhu, Y.; Chan, K.H.; Qin, L.; Li, Y.; Wang, Q.; Chan, J.F.; Du, L.; Yu, F.; et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 2014, 5, 3067. [Google Scholar] [CrossRef] [Green Version]
  64. Zheng, Q.; Deng, Y.; Liu, J.; van der Hoek, L.; Berkhout, B.; Lu, M. Core structure of S2 from the human coronavirus NL63 spike glycoprotein. Biochemistry 2006, 45, 15205–15215. [Google Scholar] [CrossRef] [PubMed]
  65. Xu, Y.; Lou, Z.; Liu, Y.; Pang, H.; Tien, P.; Gao, G.F.; Rao, Z. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J. Biol. Chem. 2004, 279, 49414–49419. [Google Scholar] [CrossRef] [PubMed]
  66. Xu, Y.; Liu, Y.; Lou, Z.; Qin, L.; Li, X.; Bai, Z.; Pang, H.; Tien, P.; Gao, G.F.; Rao, Z. Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J. Biol. Chem. 2004, 279, 30514–30522. [Google Scholar] [CrossRef]
  67. Hofmann, H.; Hattermann, K.; Marzi, A.; Gramberg, T.; Geier, M.; Krumbiegel, M.; Kuate, S.; Uberla, K.; Niedrig, M.; Pohlmann, S. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J. Virol. 2004, 78, 6134–6142. [Google Scholar] [CrossRef]
  68. Holmes, K.V. SARS-associated coronavirus. N. Engl. J. Med. 2003, 348, 1948–1951. [Google Scholar] [CrossRef]
  69. Li, F.; Berardi, M.; Li, W.; Farzan, M.; Dormitzer, P.R.; Harrison, S.C. Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain. J. Virol. 2006, 80, 6794–6800. [Google Scholar] [CrossRef] [PubMed]
  70. Wong, S.K.; Li, W.; Moore, M.J.; Choe, H.; Farzan, M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 2004, 279, 3197–3201. [Google Scholar] [CrossRef] [PubMed]
  71. Xiao, X.; Chakraborti, S.; Dimitrov, A.S.; Gramatikoff, K.; Dimitrov, D.S. The SARS-CoV S glycoprotein: Expression and functional characterization. Biochem. Biophys. Res. Commun. 2003, 312, 1159–1164. [Google Scholar] [CrossRef] [PubMed]
  72. Zhang, Y.; Zheng, N.; Hao, P.; Cao, Y.; Zhong, Y. A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2. Comput. Biol. Chem. 2005, 29, 254–257. [Google Scholar] [CrossRef] [PubMed]
  73. He, Y.; Li, J.; Jiang, S. A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Biochem. Biophys. Res. Commun. 2006, 344, 106–113. [Google Scholar] [CrossRef] [PubMed]
  74. Sainz, B.J.; Rausch, J.M.; Gallaher, W.R.; Garry, R.F.; Wimley, W.C. Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein. J. Virol. 2005, 79, 7195–7206. [Google Scholar] [CrossRef] [PubMed]
  75. Yang, Z.Y.; Huang, Y.; Ganesh, L.; Leung, K.; Kong, W.P.; Schwartz, O.; Subbarao, K.; Nabel, G.J. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 2004, 78, 5642–5650. [Google Scholar] [CrossRef] [PubMed]
  76. Han, D.P.; Lohani, M.; Cho, M.W. Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. J. Virol. 2007, 81, 12029–12039. [Google Scholar] [CrossRef]
  77. Graham, R.L.; Donaldson, E.F.; Baric, R.S. A decade after SARS: Strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 2013, 11, 836–848. [Google Scholar] [CrossRef]
  78. Keng, C.T.; Zhang, A.; Shen, S.; Lip, K.M.; Fielding, B.C.; Tan, T.H.; Chou, C.F.; Loh, C.B.; Wang, S.; Fu, J.; et al. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agents. J. Virol. 2005, 79, 3289–3296. [Google Scholar] [CrossRef]
  79. Zhou, T.; Wang, H.; Luo, D.; Rowe, T.; Wang, Z.; Hogan, R.J.; Qiu, S.; Bunzel, R.J.; Huang, G.; Mishra, V.; et al. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J. Virol. 2004, 78, 7217–7226. [Google Scholar] [CrossRef]
  80. Bukreyev, A.; Lamirande, E.W.; Buchholz, U.J.; Vogel, L.N.; Elkins, W.R.; St, C.M.; Murphy, B.R.; Subbarao, K.; Collins, P.L. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004, 363, 2122–2127. [Google Scholar] [CrossRef]
  81. Yang, Z.Y.; Kong, W.P.; Huang, Y.; Roberts, A.; Murphy, B.R.; Subbarao, K.; Nabel, G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004, 428, 561–564. [Google Scholar] [CrossRef]
  82. Kam, Y.W.; Kien, F.; Roberts, A.; Cheung, Y.C.; Lamirande, E.W.; Vogel, L.; Chu, S.L.; Tse, J.; Guarner, J.; Zaki, S.R.; et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 2007, 25, 729–740. [Google Scholar] [CrossRef] [PubMed]
  83. Czub, M.; Weingartl, H.; Czub, S.; He, R.; Cao, J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 2005, 23, 2273–2279. [Google Scholar] [CrossRef]
  84. Weingartl, H.; Czub, M.; Czub, S.; Neufeld, J.; Marszal, P.; Gren, J.; Smith, G.; Jones, S.; Proulx, R.; Deschambault, Y.; et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 2004, 78, 12672–12676. [Google Scholar] [CrossRef] [PubMed]
  85. Tai, W.; Wang, Y.; Fett, C.A.; Zhao, G.; Li, F.; Perlman, S.; Jiang, S.; Zhou, Y.; Du, L. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J. Virol. 2017, 91, e01651-16. [Google Scholar] [CrossRef] [PubMed]
  86. Wang, L.; Shi, W.; Joyce, M.G.; Modjarrad, K.; Zhang, Y.; Leung, K.; Lees, C.R.; Zhou, T.; Yassine, H.M.; Kanekiyo, M.; et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 2015, 6, 7712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Gilbert, S.C.; Warimwe, G.M. Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology. Vaccine 2017, 35, 4461–4464. [Google Scholar] [CrossRef]
  88. Kim, E.; Okada, K.; Kenniston, T.; Raj, V.S.; AlHajri, M.M.; Farag, E.A.; AlHajri, F.; Osterhaus, A.D.; Haagmans, B.L.; Gambotto, A. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine 2014, 32, 5975–5982. [Google Scholar] [CrossRef]
  89. Chi, H.; Zheng, X.; Wang, X.; Wang, C.; Wang, H.; Gai, W.; Perlman, S.; Yang, S.; Zhao, J.; Xia, X. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine 2017, 35, 2069–2075. [Google Scholar] [CrossRef] [Green Version]
  90. Al-Amri, S.S.; Abbas, A.T.; Siddiq, L.A.; Alghamdi, A.; Sanki, M.A.; Al-Muhanna, M.K.; Alhabbab, R.Y.; Azhar, E.I.; Li, X.; Hashem, A.M. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein. Sci. Rep. 2017, 7, 44875. [Google Scholar] [CrossRef]
  91. Modjarrad, K. MERS-CoV vaccine candidates in development: The current landscape. Vaccine 2016, 34, 2982–2987. [Google Scholar] [CrossRef] [Green Version]
  92. Zhao, J.; Zhao, J.; Mangalam, A.K.; Channappanavar, R.; Fett, C.; Meyerholz, D.K.; Agnihothram, S.; Baric, R.S.; David, C.S.; Perlman, S. Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity 2016, 44, 1379–1391. [Google Scholar] [CrossRef]
  93. Roper, R.L.; Rehm, K.E. SARS vaccines: Where are we? Expert Rev. Vaccines 2009, 8, 887–898. [Google Scholar] [CrossRef] [PubMed]
  94. Lin, J.; Zhang, J.; Su, N.; Xu, J.; Wang, N.; Chen, J.; Chen, X.; Liu, Y.; Gao, H.; Jia, Y.; et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir. Ther. 2007, 12, 1107–1113. [Google Scholar] [PubMed]
  95. Deng, Y.; Lan, J.; Bao, L.; Huang, B.; Ye, F.; Chen, Y.; Yao, Y.; Wang, W.; Qin, C.; Tan, W. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg. Microbes Infect. 2018, 7, 60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. See, R.H.; Zakhartchouk, A.N.; Petric, M.; Lawrence, D.J.; Mok, C.P.; Hogan, R.J.; Rowe, T.; Zitzow, L.A.; Karunakaran, K.P.; Hitt, M.M.; et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. Gen. Virol. 2006, 87, 641–650. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  97. Enjuanes, L.; Dediego, M.L.; Alvarez, E.; Deming, D.; Sheahan, T.; Baric, R. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 2008, 133, 45–62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  98. Bolles, M.; Deming, D.; Long, K.; Agnihothram, S.; Whitmore, A.; Ferris, M.; Funkhouser, W.; Gralinski, L.; Totura, A.; Heise, M.; et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 2011, 85, 12201–12215. [Google Scholar] [CrossRef] [PubMed]
  99. Ishioka, T.; Kimura, H.; Kita, H.; Obuchi, M.; Hoshino, H.; Noda, M.; Nishina, A.; Kozawa, K.; Kato, M. Effects of respiratory syncytial virus infection and major basic protein derived from eosinophils in pulmonary alveolar epithelial cells (A549). Cell Biol. Int. 2011, 35, 467–474. [Google Scholar] [CrossRef] [PubMed]
  100. Fett, C.; DeDiego, M.L.; Regla-Nava, J.A.; Enjuanes, L.; Perlman, S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J. Virol. 2013, 87, 6551–6559. [Google Scholar] [CrossRef] [PubMed]
  101. Graham, R.L.; Becker, M.M.; Eckerle, L.D.; Bolles, M.; Denison, M.R.; Baric, R.S. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat. Med. 2012, 18, 1820–1826. [Google Scholar] [CrossRef] [Green Version]
  102. Almazan, F.; DeDiego, M.L.; Sola, I.; Zuniga, S.; Nieto-Torres, J.L.; Marquez-Jurado, S.; Andres, G.; Enjuanes, L. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio 2013, 4, e613–e650. [Google Scholar] [CrossRef] [PubMed]
  103. Vignuzzi, M.; Wendt, E.; Andino, R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 2008, 14, 154–161. [Google Scholar] [CrossRef] [PubMed]
  104. Roberts, A.; Vogel, L.; Guarner, J.; Hayes, N.; Murphy, B.; Zaki, S.; Subbarao, K. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J. Virol. 2005, 79, 503–511. [Google Scholar] [CrossRef] [PubMed]
  105. Deming, D.; Sheahan, T.; Heise, M.; Yount, B.; Davis, N.; Sims, A.; Suthar, M.; Harkema, J.; Whitmore, A.; Pickles, R.; et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006, 3, e525. [Google Scholar] [CrossRef] [PubMed]
  106. Chen, Z.; Zhang, L.; Qin, C.; Ba, L.; Yi, C.E.; Zhang, F.; Wei, Q.; He, T.; Yu, W.; Yu, J.; et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 2005, 79, 2678–2688. [Google Scholar] [CrossRef] [PubMed]
  107. Lan, J.; Yao, Y.; Deng, Y.; Chen, H.; Lu, G.; Wang, W.; Bao, L.; Deng, W.; Wei, Q.; Gao, G.F.; et al. Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge. EBioMedicine 2015, 2, 1438–1446. [Google Scholar] [CrossRef] [Green Version]
  108. Jiaming, L.; Yanfeng, Y.; Yao, D.; Yawei, H.; Linlin, B.; Baoying, H.; Jinghua, Y.; Gao, G.F.; Chuan, Q.; Wenjie, T. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine 2017, 35, 10–18. [Google Scholar] [CrossRef]
  109. Bisht, H.; Roberts, A.; Vogel, L.; Subbarao, K.; Moss, B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 2005, 334, 160–165. [Google Scholar] [CrossRef] [Green Version]
  110. Woo, P.C.; Lau, S.K.; Tsoi, H.W.; Chen, Z.W.; Wong, B.H.; Zhang, L.; Chan, J.K.; Wong, L.P.; He, W.; Ma, C.; et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 2005, 23, 4959–4968. [Google Scholar] [CrossRef]
  111. Shi, S.; Peng, J.; Li, Y.; Qin, C.; Liang, G.; Xu, L.; Yang, Y.; Wang, J.; Sun, Q. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Mol. Immunol. 2006, 43, 1791–1798. [Google Scholar] [CrossRef]
  112. Gupta, V.; Tabiin, T.M.; Sun, K.; Chandrasekaran, A.; Anwar, A.; Yang, K.; Chikhlikar, P.; Salmon, J.; Brusic, V.; Marques, E.T.; et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology 2006, 347, 127–139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  113. Zhuang, M.; Jiang, H.; Suzuki, Y.; Li, X.; Xiao, P.; Tanaka, T.; Ling, H.; Yang, B.; Saitoh, H.; Zhang, L.; et al. Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection. Antivir. Res. 2009, 82, 73–81. [Google Scholar] [CrossRef]
  114. Hu, H.; Li, L.; Kao, R.Y.; Kou, B.; Wang, Z.; Zhang, L.; Zhang, H.; Hao, Z.; Tsui, W.H.; Ni, A.; et al. Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. J. Comb. Chem. 2005, 7, 648–656. [Google Scholar] [CrossRef]
  115. Zheng, B.J.; Guan, Y.; Hez, M.L.; Sun, H.; Du, L.; Zheng, Y.; Wong, K.L.; Chen, H.; Chen, Y.; Lu, L.; et al. Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. Antivir. Ther. 2005, 10, 393–403. [Google Scholar] [PubMed]
  116. Bosch, B.J.; Martina, B.E.; Van Der Zee, R.; Lepault, J.; Haijema, B.J.; Versluis, C.; Heck, A.J.; De Groot, R.; Osterhaus, A.D.; Rottier, P.J. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. USA 2004, 101, 8455–8460. [Google Scholar] [CrossRef] [Green Version]
  117. Yuan, K.; Yi, L.; Chen, J.; Qu, X.; Qing, T.; Rao, X.; Jiang, P.; Hu, J.; Xiong, Z.; Nie, Y.; et al. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem. Biophys. Res. Commun. 2004, 319, 746–752. [Google Scholar] [CrossRef]
  118. McRoy, W.C.; Baric, R.S. Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion. J. Virol. 2008, 82, 1414–1424. [Google Scholar] [CrossRef]
  119. He, Y.; Li, J.; Heck, S.; Lustigman, S.; Jiang, S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: Implication for vaccine design. J. Virol. 2006, 80, 5757–5767. [Google Scholar] [CrossRef]
  120. He, Y.; Li, J.; Li, W.; Lustigman, S.; Farzan, M.; Jiang, S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J. Immunol. 2006, 176, 6085–6092. [Google Scholar] [CrossRef] [PubMed]
  121. He, Y.; Zhu, Q.; Liu, S.; Zhou, Y.; Yang, B.; Li, J.; Jiang, S. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: Importance for designing SARS vaccines. Virology 2005, 334, 74–82. [Google Scholar] [CrossRef]
  122. Lai, S.C.; Chong, P.C.; Yeh, C.T.; Liu, L.S.; Jan, J.T.; Chi, H.Y.; Liu, H.W.; Chen, A.; Wang, Y.C. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). J. Biomed. Sci. 2005, 12, 711–727. [Google Scholar] [CrossRef] [PubMed]
  123. Nie, Y.; Wang, G.; Shi, X.; Zhang, H.; Qiu, Y.; He, Z.; Wang, W.; Lian, G.; Yin, X.; Du, L.; et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J. Infect. Dis. 2004, 190, 1119–1126. [Google Scholar] [CrossRef]
  124. Traggiai, E.; Becker, S.; Subbarao, K.; Kolesnikova, L.; Uematsu, Y.; Gismondo, M.R.; Murphy, B.R.; Rappuoli, R.; Lanzavecchia, A. An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat. Med. 2004, 10, 871–875. [Google Scholar] [CrossRef]
  125. Rockx, B.; Corti, D.; Donaldson, E.; Sheahan, T.; Stadler, K.; Lanzavecchia, A.; Baric, R. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 2008, 82, 3220–3235. [Google Scholar] [CrossRef] [PubMed]
  126. Zhu, Z.; Chakraborti, S.; He, Y.; Roberts, A.; Sheahan, T.; Xiao, X.; Hensley, L.E.; Prabakaran, P.; Rockx, B.; Sidorov, I.A.; et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. USA 2007, 104, 12123–12128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  127. Coughlin, M.; Lou, G.; Martinez, O.; Masterman, S.K.; Olsen, O.A.; Moksa, A.A.; Farzan, M.; Babcook, J.S.; Prabhakar, B.S. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 2007, 361, 93–102. [Google Scholar] [CrossRef]
  128. van den Brink, E.N.; Ter Meulen, J.; Cox, F.; Jongeneelen, M.A.; Thijsse, A.; Throsby, M.; Marissen, W.E.; Rood, P.M.; Bakker, A.B.; Gelderblom, H.R.; et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J. Virol. 2005, 79, 1635–1644. [Google Scholar] [CrossRef] [PubMed]
  129. Sui, J.; Li, W.; Murakami, A.; Tamin, A.; Matthews, L.J.; Wong, S.K.; Moore, M.J.; Tallarico, A.S.; Olurinde, M.; Choe, H.; et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. USA 2004, 101, 2536–2541. [Google Scholar] [CrossRef] [Green Version]
  130. Liu, S.; Xiao, G.; Chen, Y.; He, Y.; Niu, J.; Escalante, C.R.; Xiong, H.; Farmar, J.; Debnath, A.K.; Tien, P.; et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004, 363, 938–947. [Google Scholar] [CrossRef]
  131. Corti, D.; Zhao, J.; Pedotti, M.; Simonelli, L.; Agnihothram, S.; Fett, C.; Fernandez-Rodriguez, B.; Foglierini, M.; Agatic, G.; Vanzetta, F.; et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc. Natl. Acad. Sci. USA 2015, 112, 10473–10478. [Google Scholar] [CrossRef]
  132. Li, Y.; Wan, Y.; Liu, P.; Zhao, J.; Lu, G.; Qi, J.; Wang, Q.; Lu, X.; Wu, Y.; Liu, W.; et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 2015, 25, 1237–1249. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  133. Du, L.; Zhao, G.; Yang, Y.; Qiu, H.; Wang, L.; Kou, Z.; Tao, X.; Yu, H.; Sun, S.; Tseng, C.T.; et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J. Virol. 2014, 88, 7045–7053. [Google Scholar] [CrossRef] [PubMed]
  134. Raj, V.S.; Smits, S.L.; Provacia, L.B.; van den Brand, J.M.; Wiersma, L.; Ouwendijk, W.J.; Bestebroer, T.M.; Spronken, M.I.; van Amerongen, G.; Rottier, P.J.; et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J. Virol. 2014, 88, 1834–1838. [Google Scholar] [CrossRef] [PubMed]
  135. Zhou, N.; Pan, T.; Zhang, J.; Li, Q.; Zhang, X.; Bai, C.; Huang, F.; Peng, T.; Zhang, J.; Liu, C.; et al. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). J. Biol. Chem. 2016, 291, 9218–9232. [Google Scholar] [CrossRef]
  136. Gierer, S.; Bertram, S.; Kaup, F.; Wrensch, F.; Heurich, A.; Kramer-Kuhl, A.; Welsch, K.; Winkler, M.; Meyer, B.; Drosten, C.; et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J. Virol. 2013, 87, 5502–5511. [Google Scholar] [CrossRef] [PubMed]
  137. Shirato, K.; Kawase, M.; Matsuyama, S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol. 2013, 87, 12552–12561. [Google Scholar] [CrossRef]
  138. Zhou, Y.; Vedantham, P.; Lu, K.; Agudelo, J.; Carrion, R.; Nunneley, J.W.; Barnard, D.; Pöhlmann, S.; McKerrow, J.H.; Renslo, A.R.; Simmons, G. Protease inhibitors targeting coronavirus and filovirus entry. Antivir. Res. 2015, 116, 76–84. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  139. Momattin, H.; Mohammed, K.; Zumla, A.; Memish, Z.A.; Al-Tawfiq, J.A. Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–possible lessons from a systematic review of SARS-CoV therapy. Int. J. Infect. Dis. 2013, 17, e792–e798. [Google Scholar] [CrossRef]
  140. Hart, B.J.; Dyall, J.; Postnikova, E.; Zhou, H.; Kindrachuk, J.; Johnson, R.F.; Olinger, G.J.; Frieman, M.B.; Holbrook, M.R.; Jahrling, P.B.; et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J. Gen. Virol. 2014, 95, 571–577. [Google Scholar] [CrossRef]
  141. ter Meulen, J.; van den Brink, E.N.; Poon, L.L.; Marissen, W.E.; Leung, C.S.; Cox, F.; Cheung, C.Y.; Bakker, A.Q.; Bogaards, J.A.; van Deventer, E.; et al. Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med. 2006, 3, e237. [Google Scholar] [CrossRef]
  142. Zhang, J.S.; Chen, J.T.; Liu, Y.X.; Zhang, Z.S.; Gao, H.; Liu, Y.; Wang, X.; Ning, Y.; Liu, Y.F.; Gao, Q.; et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J. Med. Virol. 2005, 77, 147–150. [Google Scholar] [CrossRef]
  143. Miyoshi-Akiyama, T.; Ishida, I.; Fukushi, M.; Yamaguchi, K.; Matsuoka, Y.; Ishihara, T.; Tsukahara, M.; Hatakeyama, S.; Itoh, N.; Morisawa, A.; et al. Fully Human Monoclonal Antibody Directed to Proteolytic Cleavage Site in Severe Acute Respiratory Syndrome (SARS) Coronavirus S Protein Neutralizes the Virus in a Rhesus Macaque SARS Model. J. Infect. Dis. 2011, 203, 1574–1581. [Google Scholar] [CrossRef] [Green Version]
  144. Wang, Q.; Zhang, L.; Kuwahara, K.; Li, L.; Liu, Z.; Li, T.; Zhu, H.; Liu, J.; Xu, Y.; Xie, J.; et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect. Dis. 2016, 2, 361–376. [Google Scholar] [CrossRef]
  145. Chen, Z.; Bao, L.; Chen, C.; Zou, T.; Xue, Y.; Li, F.; Lv, Q.; Gu, S.; Gao, X.; Cui, S.; et al. Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset. J. Infect. Dis. 2017, 215, 1807–1815. [Google Scholar] [CrossRef]
  146. Stockman, L.J.; Bellamy, R.; Garner, P.; Low, D. SARS: Systematic Review of Treatment Effects. PLoS Med. 2006, 3, e343. [Google Scholar] [CrossRef]
  147. Chan, P.K.S.; Tang, J.W.; Hui, D.S.C. SARS: Clinical presentation, transmission, pathogenesis and treatment options. Clin. Sci. 2006, 110, 193–204. [Google Scholar] [CrossRef]
  148. Chan, J.F.; Yao, Y.; Yeung, M.; Deng, W.; Bao, L.; Jia, L.; Li, F.; Xiao, C.; Gao, H.; Yu, P.; et al. Treatment with Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J. Infect. Dis. 2015, 212, 1904–1913. [Google Scholar] [CrossRef]
  149. Subbarao, K.; McAuliffe, J.; Vogel, L.; Fahle, G.; Fischer, S.; Tatti, K.; Packard, M.; Shieh, W.J.; Zaki, S.; Murphy, B. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol. 2004, 78, 3572–3577. [Google Scholar] [CrossRef]
  150. Wentworth, D.E.; Gillim-Ross, L.; Espina, N.; Bernard, K.A. Mice susceptible to SARS coronavirus. Emerg. Infect. Dis. 2004, 10, 1293–1296. [Google Scholar] [CrossRef]
  151. Glass, W.G.; Subbarao, K.; Murphy, B.; Murphy, P.M. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J. Immunol. 2004, 173, 4030–4039. [Google Scholar] [CrossRef]
  152. Yang, X.H.; Deng, W.; Tong, Z.; Liu, Y.X.; Zhang, L.F.; Zhu, H.; Gao, H.; Huang, L.; Liu, Y.L.; Ma, C.M.; et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp. Med. 2007, 57, 450–459. [Google Scholar] [PubMed]
  153. Roberts, A.; Paddock, C.; Vogel, L.; Butler, E.; Zaki, S.; Subbarao, K. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J. Virol. 2005, 79, 5833–5838. [Google Scholar] [CrossRef] [PubMed]
  154. Hogan, R.J.; Gao, G.; Rowe, T.; Bell, P.; Flieder, D.; Paragas, J.; Kobinger, G.P.; Wivel, N.A.; Crystal, R.G.; Boyer, J.; et al. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J. Virol. 2004, 78, 11416–11421. [Google Scholar] [CrossRef]
  155. Frieman, M.; Yount, B.; Agnihothram, S.; Page, C.; Donaldson, E.; Roberts, A.; Vogel, L.; Woodruff, B.; Scorpio, D.; Subbarao, K.; et al. Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J. Virol. 2012, 86, 884–897. [Google Scholar] [CrossRef] [PubMed]
  156. Zhao, J.; Zhao, J.; Legge, K.; Perlman, S. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J. Clin. Investig. 2011, 121, 4921–4930. [Google Scholar] [CrossRef]
  157. Zhao, J.; Zhao, J.; Perlman, S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 2010, 84, 9318–9325. [Google Scholar] [CrossRef] [PubMed]
  158. Zhao, J.; Zhao, J.; Van Rooijen, N.; Perlman, S. Evasion by stealth: Inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. PLoS Pathog. 2009, 5, e1000636. [Google Scholar] [CrossRef] [PubMed]
  159. Sheahan, T.; Morrison, T.E.; Funkhouser, W.; Uematsu, S.; Akira, S.; Baric, R.S.; Heise, M.T. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog. 2008, 4, e1000240. [Google Scholar] [CrossRef]
  160. Li, C.K.; Wu, H.; Yan, H.; Ma, S.; Wang, L.; Zhang, M.; Tang, X.; Temperton, N.J.; Weiss, R.A.; Brenchley, J.M.; et al. T cell responses to whole SARS coronavirus in humans. J. Immunol. 2008, 181, 5490–5500. [Google Scholar] [CrossRef]
  161. Chen, W.; Xu, Z.; Mu, J.; Yang, L.; Gan, H.; Mu, F.; Fan, B.; He, B.; Huang, S.; You, B.; et al. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. J. Med. Microbiol. 2004, 53, 435–438. [Google Scholar] [CrossRef] [Green Version]
  162. Spruth, M.; Kistner, O.; Savidis-Dacho, H.; Hitter, E.; Crowe, B.; Gerencer, M.; Bruhl, P.; Grillberger, L.; Reiter, M.; Tauer, C.; et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 2006, 24, 652–661. [Google Scholar] [CrossRef]
  163. Greenough, T.C.; Babcock, G.J.; Roberts, A.; Hernandez, H.J.; Thomas, W.J.; Coccia, J.A.; Graziano, R.F.; Srinivasan, M.; Lowy, I.; Finberg, R.W.; et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J. Infect. Dis. 2005, 191, 507–514. [Google Scholar] [CrossRef]
  164. Kapadia, S.U.; Rose, J.K.; Lamirande, E.; Vogel, L.; Subbarao, K.; Roberts, A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005, 340, 174–182. [Google Scholar] [CrossRef] [Green Version]
  165. Stadler, K.; Roberts, A.; Becker, S.; Vogel, L.; Eickmann, M.; Kolesnikova, L.; Klenk, H.D.; Murphy, B.; Rappuoli, R.; Abrignani, S.; et al. SARS vaccine protective in mice. Emerg. Infect. Dis. 2005, 11, 1312–1314. [Google Scholar] [CrossRef]
  166. Bisht, H.; Roberts, A.; Vogel, L.; Bukreyev, A.; Collins, P.L.; Murphy, B.R.; Subbarao, K.; Moss, B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA 2004, 101, 6641–6646. [Google Scholar] [CrossRef] [Green Version]
  167. Schaecher, S.R.; Stabenow, J.; Oberle, C.; Schriewer, J.; Buller, R.M.; Sagartz, J.E.; Pekosz, A. An immunosuppressed Syrian golden hamster model for SARS-CoV infection. Virology 2008, 380, 312–321. [Google Scholar] [CrossRef] [Green Version]
  168. Luo, D.; Ni, B.; Zhao, G.; Jia, Z.; Zhou, L.; Pacal, M.; Zhang, L.; Zhang, S.; Xing, L.; Lin, Z.; et al. Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab’)2. Viral Immunol. 2007, 20, 495–502. [Google Scholar] [CrossRef]
  169. Subbarao, K.; Roberts, A. Is there an ideal animal model for SARS? Trends Microbiol. 2006, 14, 299–303. [Google Scholar] [CrossRef]
  170. Roberts, A.; Thomas, W.D.; Guarner, J.; Lamirande, E.W.; Babcock, G.J.; Greenough, T.C.; Vogel, L.; Hayes, N.; Sullivan, J.L.; Zaki, S.; et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J. Infect. Dis. 2006, 193, 685–692. [Google Scholar] [CrossRef]
  171. Martina, B.E.; Haagmans, B.L.; Kuiken, T.; Fouchier, R.A.; Rimmelzwaan, G.F.; Van Amerongen, G.; Peiris, J.S.; Lim, W.; Osterhaus, A.D. Virology: SARS virus infection of cats and ferrets. Nature 2003, 425, 915. [Google Scholar] [CrossRef]
  172. van den Brand, J.M.; Haagmans, B.L.; Leijten, L.; van Riel, D.; Martina, B.E.; Osterhaus, A.D.; Kuiken, T. Pathology of experimental SARS coronavirus infection in cats and ferrets. Vet. Pathol. 2008, 45, 551–562. [Google Scholar] [CrossRef]
  173. Darnell, M.E.; Plant, E.P.; Watanabe, H.; Byrum, R.; St, C.M.; Ward, J.M.; Taylor, D.R. Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J. Infect. Dis. 2007, 196, 1329–1338. [Google Scholar] [CrossRef]
  174. ter Meulen, J.; Bakker, A.B.; van den Brink, E.N.; Weverling, G.J.; Martina, B.E.; Haagmans, B.L.; Kuiken, T.; de Kruif, J.; Preiser, W.; Spaan, W.; et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004, 363, 2139–2141. [Google Scholar] [CrossRef]
  175. See, R.H.; Petric, M.; Lawrence, D.J.; Mok, C.P.; Rowe, T.; Zitzow, L.A.; Karunakaran, K.P.; Voss, T.G.; Brunham, R.C.; Gauldie, J.; et al. Severe acute respiratory syndrome vaccine efficacy in ferrets: Whole killed virus and adenovirus-vectored vaccines. J. Gen. Virol. 2008, 89, 2136–2146. [Google Scholar] [CrossRef]
  176. Qin, C.; Wang, J.; Wei, Q.; She, M.; Marasco, W.A.; Jiang, H.; Tu, X.; Zhu, H.; Ren, L.; Gao, H.; et al. An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J. Pathol. 2005, 206, 251–259. [Google Scholar] [CrossRef]
  177. McAuliffe, J.; Vogel, L.; Roberts, A.; Fahle, G.; Fischer, S.; Shieh, W.J.; Butler, E.; Zaki, S.; St, C.M.; Murphy, B.; et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 2004, 330, 8–15. [Google Scholar] [CrossRef] [Green Version]
  178. Rowe, T.; Gao, G.; Hogan, R.J.; Crystal, R.G.; Voss, T.G.; Grant, R.L.; Bell, P.; Kobinger, G.P.; Wivel, N.A.; Wilson, J.M. Macaque model for severe acute respiratory syndrome. J. Virol. 2004, 78, 11401–11404. [Google Scholar] [CrossRef]
  179. Li, B.; Tang, Q.; Cheng, D.; Qin, C.; Xie, F.Y.; Wei, Q.; Xu, J.; Liu, Y.; Zheng, B.; Woodle, M.C.; et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 2005, 11, 944–951. [Google Scholar] [CrossRef]
  180. Liu, L.; Wei, Q.; Nishiura, K.; Peng, J.; Wang, H.; Midkiff, C.; Alvarez, X.; Qin, C.; Lackner, A.; Chen, Z. Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques. Mucosal Immunol. 2016, 9, 1089–1101. [Google Scholar] [CrossRef]
  181. Fouchier, R.A.; Kuiken, T.; Schutten, M.; van Amerongen, G.; van Doornum, G.J.; van den Hoogen, B.G.; Peiris, M.; Lim, W.; Stohr, K.; Osterhaus, A.D. Aetiology: Koch’s postulates fulfilled for SARS virus. Nature 2003, 423, 240. [Google Scholar] [CrossRef]
  182. Kuiken, T.; Fouchier, R.A.; Schutten, M.; Rimmelzwaan, G.F.; van Amerongen, G.; van Riel, D.; Laman, J.D.; de Jong, T.; van Doornum, G.; Lim, W.; et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003, 362, 263–270. [Google Scholar] [CrossRef]
  183. Greenough, T.C.; Carville, A.; Coderre, J.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Mansfield, K. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. Am. J. Pathol. 2005, 167, 455–463. [Google Scholar] [CrossRef]
  184. Lawler, J.V.; Endy, T.P.; Hensley, L.E.; Garrison, A.; Fritz, E.A.; Lesar, M.; Baric, R.S.; Kulesh, D.A.; Norwood, D.A.; Wasieloski, L.P.; et al. Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med. 2006, 3, e149. [Google Scholar] [CrossRef]
  185. Roberts, A.; Subbarao, K. Animal models for SARS. Adv. Exp. Med. Biol. 2006, 581, 463–471. [Google Scholar]
  186. Chen, Y.; Liu, L.; Wei, Q.; Zhu, H.; Jiang, H.; Tu, X.; Qin, C.; Chen, Z. Rhesus angiotensin converting enzyme 2 supports entry of severe acute respiratory syndrome coronavirus in Chinese macaques. Virology 2008, 381, 89–97. [Google Scholar] [CrossRef] [Green Version]
  187. Cockrell, A.S.; Peck, K.M.; Yount, B.L.; Agnihothram, S.S.; Scobey, T.; Curnes, N.R.; Baric, R.S.; Heise, M.T. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J. Virol. 2014, 88, 5195–5199. [Google Scholar] [CrossRef]
  188. Coleman, C.M.; Matthews, K.L.; Goicochea, L.; Frieman, M.B. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J. Gen. Virol. 2014, 95, 408–412. [Google Scholar] [CrossRef]
  189. de Wit, E.; Feldmann, F.; Horne, E.; Martellaro, C.; Haddock, E.; Bushmaker, T.; Rosenke, K.; Okumura, A.; Rosenke, R.; Saturday, G.; et al. Domestic Pig Unlikely Reservoir for MERS-CoV. Emerg. Infect. Dis. 2017, 23, 985–988. [Google Scholar] [CrossRef] [Green Version]
  190. Peck, K.M.; Scobey, T.; Swanstrom, J.; Jensen, K.L.; Burch, C.L.; Baric, R.S.; Heise, M.T. Permissivity of Dipeptidyl Peptidase 4 Orthologs to Middle East Respiratory Syndrome Coronavirus Is Governed by Glycosylation and Other Complex Determinants. J. Virol. 2017, 91, e00534-17. [Google Scholar] [CrossRef]
  191. Haagmans, B.L.; van den Brand, J.M.; Provacia, L.B.; Raj, V.S.; Stittelaar, K.J.; Getu, S.; de Waal, L.; Bestebroer, T.M.; van Amerongen, G.; Verjans, G.M.; et al. Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. J. Virol. 2015, 89, 6131–6135. [Google Scholar] [CrossRef]
  192. de Wit, E.; Prescott, J.; Baseler, L.; Bushmaker, T.; Thomas, T.; Lackemeyer, M.G.; Martellaro, C.; Milne-Price, S.; Haddock, E.; Haagmans, B.L.; et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS ONE 2013, 8, e69127. [Google Scholar] [CrossRef]
  193. Li, K.; Wohlford-Lenane, C.L.; Channappanavar, R.; Park, J.E.; Earnest, J.T.; Bair, T.B.; Bates, A.M.; Brogden, K.A.; Flaherty, H.A.; Gallagher, T.; et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc. Natl. Acad. Sci. USA 2017, 114, E3119–E3128. [Google Scholar] [CrossRef]
  194. Zhao, G.; Jiang, Y.; Qiu, H.; Gao, T.; Zeng, Y.; Guo, Y.; Yu, H.; Li, J.; Kou, Z.; Du, L.; et al. Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. PLoS ONE 2015, 10, e145561. [Google Scholar] [CrossRef]
  195. Zhao, J.; Li, K.; Wohlford-Lenane, C.; Agnihothram, S.S.; Fett, C.; Zhao, J.; Gale, M.J.; Baric, R.S.; Enjuanes, L.; Gallagher, T.; et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. USA 2014, 111, 4970–4975. [Google Scholar] [CrossRef] [Green Version]
  196. Tseng, C.T.; Huang, C.; Newman, P.; Wang, N.; Narayanan, K.; Watts, D.M.; Makino, S.; Packard, M.M.; Zaki, S.R.; Chan, T.S.; et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J. Virol. 2007, 81, 1162–1173. [Google Scholar] [CrossRef]
  197. Cockrell, A.S.; Yount, B.L.; Scobey, T.; Jensen, K.; Douglas, M.; Beall, A.; Tang, X.C.; Marasco, W.A.; Heise, M.T.; Baric, R.S. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat. Microbiol. 2016, 2, 16226. [Google Scholar] [CrossRef] [Green Version]
  198. Haagmans, B.L.; van den Brand, J.M.; Raj, V.S.; Volz, A.; Wohlsein, P.; Smits, S.L.; Schipper, D.; Bestebroer, T.M.; Okba, N.; Fux, R.; et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 2016, 351, 77–81. [Google Scholar] [CrossRef]
  199. Adney, D.R.; Bielefeldt-Ohmann, H.; Hartwig, A.E.; Bowen, R.A. Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas. Emerg. Infect. Dis. 2016, 22, 1031–1037. [Google Scholar] [CrossRef] [Green Version]
  200. Crameri, G.; Durr, P.A.; Klein, R.; Foord, A.; Yu, M.; Riddell, S.; Haining, J.; Johnson, D.; Hemida, M.G.; Barr, J.; et al. Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus. Emerg. Infect. Dis. 2016, 22, 1071–1074. [Google Scholar] [CrossRef] [Green Version]
  201. Yao, Y.; Bao, L.; Deng, W.; Xu, L.; Li, F.; Lv, Q.; Yu, P.; Chen, T.; Xu, Y.; Zhu, H.; et al. An Animal Model of MERS Produced by Infection of Rhesus Macaques with MERS Coronavirus. J. Infect. Dis. 2013, 209, 236–242. [Google Scholar] [CrossRef]
  202. Yu, P.; Xu, Y.; Deng, W.; Bao, L.; Huang, L.; Xu, Y.; Yao, Y.; Qin, C. Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus. PLoS ONE 2017, 12, e172093. [Google Scholar] [CrossRef] [PubMed]
  203. Falzarano, D.; de Wit, E.; Feldmann, F.; Rasmussen, A.L.; Okumura, A.; Peng, X.; Thomas, M.J.; van Doremalen, N.; Haddock, E.; Nagy, L.; et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014, 10, e1004250. [Google Scholar] [CrossRef] [PubMed]
  204. Munster, V.J.; de Wit, E.; Feldmann, H. Pneumonia from human coronavirus in a macaque model. N. Engl. J. Med. 2013, 368, 1560–1562. [Google Scholar] [CrossRef] [PubMed]
  205. Falzarano, D.; de Wit, E.; Rasmussen, A.L.; Feldmann, F.; Okumura, A.; Scott, D.P.; Brining, D.; Bushmaker, T.; Martellaro, C.; Baseler, L.; et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 2013, 19, 1313–1317. [Google Scholar] [CrossRef]
  206. Johnson, R.F.; Via, L.E.; Kumar, M.R.; Cornish, J.P.; Yellayi, S.; Huzella, L.; Postnikova, E.; Oberlander, N.; Bartos, C.; Ork, B.L.; et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology 2015, 485, 422–430. [Google Scholar] [CrossRef] [Green Version]
  207. Li, W.; Greenough, T.C.; Moore, M.J.; Vasilieva, N.; Somasundaran, M.; Sullivan, J.L.; Farzan, M.; Choe, H. Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J. Virol. 2004, 78, 11429–11433. [Google Scholar] [CrossRef] [PubMed]
  208. Wu, D.; Tu, C.; Xin, C.; Xuan, H.; Meng, Q.; Liu, Y.; Yu, Y.; Guan, Y.; Jiang, Y.; Yin, X.; et al. Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates. J. Virol. 2005, 79, 2620–2625. [Google Scholar] [CrossRef]
  209. Barlan, A.; Zhao, J.; Sarkar, M.K.; Li, K.; McCray, P.J.; Perlman, S.; Gallagher, T. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J. Virol. 2014, 88, 4953–4961. [Google Scholar] [CrossRef]
  210. van Doremalen, N.; Miazgowicz, K.L.; Milne-Price, S.; Bushmaker, T.; Robertson, S.; Scott, D.; Kinne, J.; McLellan, J.S.; Zhu, J.; Munster, V.J. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J. Virol. 2014, 88, 9220–9232. [Google Scholar] [CrossRef]
Figure 1. Schematic representation of the genome organization and functional domains of S protein for SARS-CoV and MERS-CoV. The single-stranded RNA genomes of SARS-CoV and MERS-CoV encode two large genes, the ORF1a and ORF1b genes, which encode 16 non-structural proteins (nsp1–nsp16) that are highly conserved throughout coronaviruses. The structural genes encode the structural proteins, spike (S), envelope (E), membrane (M), and nucleocapsid (N), which are common features to all coronaviruses. The accessory genes (shades of green) are unique to different coronaviruses in terms of number, genomic organization, sequence, and function. The structure of each S protein is shown beneath the genome organization. The S protein mainly contains the S1 and S2 subunits. The residue numbers in each region represent their positions in the S protein of SARS and MERS, respectively. The S1/S2 cleavage sites are highlighted by dotted lines. SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; CP, cytoplasm domain; FP, fusion peptide; HR, heptad repeat; RBD, receptor-binding domain; RBM, receptor-binding motif; SP, signal peptide; TM, transmembrane domain.
Figure 1. Schematic representation of the genome organization and functional domains of S protein for SARS-CoV and MERS-CoV. The single-stranded RNA genomes of SARS-CoV and MERS-CoV encode two large genes, the ORF1a and ORF1b genes, which encode 16 non-structural proteins (nsp1–nsp16) that are highly conserved throughout coronaviruses. The structural genes encode the structural proteins, spike (S), envelope (E), membrane (M), and nucleocapsid (N), which are common features to all coronaviruses. The accessory genes (shades of green) are unique to different coronaviruses in terms of number, genomic organization, sequence, and function. The structure of each S protein is shown beneath the genome organization. The S protein mainly contains the S1 and S2 subunits. The residue numbers in each region represent their positions in the S protein of SARS and MERS, respectively. The S1/S2 cleavage sites are highlighted by dotted lines. SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; CP, cytoplasm domain; FP, fusion peptide; HR, heptad repeat; RBD, receptor-binding domain; RBM, receptor-binding motif; SP, signal peptide; TM, transmembrane domain.
Viruses 11 00059 g001
Figure 2. The life cycle of SARS-CoV and MERS-CoV in host cells. SARS-CoV and MERS-CoV enter target cells through an endosomal pathway. The S proteins of SARS and MERS bind to cellular receptor angiotensin-converting enzyme 2 (ACE2) and cellular receptor dipeptidyl peptidase 4 (DPP4), respectively. Following entry of the virus into the host cell, the viral RNA is unveiled in the cytoplasm. ORF1a and ORF1ab are translated to produce pp1a and pp1ab polyproteins, which are cleaved by the proteases that are encoded by ORF1a to yield 16 non-structural proteins that form the RNA replicase–transcriptase complex. This complex drives the production of negative-sense RNAs [(−) RNA] through both replication and transcription. During replication, full-length (−) RNA copies of the genome are produced and used as templates for full-length (+) RNA genomes. During transcription, a subset of 7–9 sub-genomic RNAs, including those encoding all structural proteins, is produced through discontinuous transcription. Although the different sub-genomic mRNAs may contain several open reading frames (ORFs), only the first ORF (that closest to the 5′ end) is translated. Viral nucleocapsids are assembled from genomic RNA and N protein in the cytoplasm, followed by budding into the lumen of the ERGIC (endoplasmic reticulum (ER)–Golgi intermediate compartment). Virions are then released from the infected cell through exocytosis. SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; S, spike; E, envelope; M, membrane; N, nucleocapsid.
Figure 2. The life cycle of SARS-CoV and MERS-CoV in host cells. SARS-CoV and MERS-CoV enter target cells through an endosomal pathway. The S proteins of SARS and MERS bind to cellular receptor angiotensin-converting enzyme 2 (ACE2) and cellular receptor dipeptidyl peptidase 4 (DPP4), respectively. Following entry of the virus into the host cell, the viral RNA is unveiled in the cytoplasm. ORF1a and ORF1ab are translated to produce pp1a and pp1ab polyproteins, which are cleaved by the proteases that are encoded by ORF1a to yield 16 non-structural proteins that form the RNA replicase–transcriptase complex. This complex drives the production of negative-sense RNAs [(−) RNA] through both replication and transcription. During replication, full-length (−) RNA copies of the genome are produced and used as templates for full-length (+) RNA genomes. During transcription, a subset of 7–9 sub-genomic RNAs, including those encoding all structural proteins, is produced through discontinuous transcription. Although the different sub-genomic mRNAs may contain several open reading frames (ORFs), only the first ORF (that closest to the 5′ end) is translated. Viral nucleocapsids are assembled from genomic RNA and N protein in the cytoplasm, followed by budding into the lumen of the ERGIC (endoplasmic reticulum (ER)–Golgi intermediate compartment). Virions are then released from the infected cell through exocytosis. SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; S, spike; E, envelope; M, membrane; N, nucleocapsid.
Viruses 11 00059 g002
Table 1. Epidemiology and biological characteristics of the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
Table 1. Epidemiology and biological characteristics of the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
SARS-CoVMERS-CoV
GenusBeta-CoVs, lineage BBeta-CoVs, lineage C
Possible Natural ReservoirBatBat
Possible Intermediary HostPalm civetDromedary camel
OriginGuangdong province, ChinaArabian Peninsula
Clinical EpidemiologyTotal global number reported to WHOMore than 8098 people2254 (from 2012 through 16 September 2018)
Affected countries2927
Number of deaths916800
MortalityMore than 10%More than 35%
Transmission regionGloballyRegionally
Transmission patternsFrom animal to human;
from human to human
The predominant receptorHuman angiotensin-converting enzyme 2 (ACE2)Human dipeptidyl peptidase 4 (DPP4 or CD26)
Receptor
distribution
Arterial and venous endothelium; arterial smooth muscle; small intestine; respiratory tract epithelium; alveolar monocytes and macrophagesRespiratory tract epithelium; kidney; small intestine; liver and prostate; activated leukocytes
Cell line susceptibilityRespiratory tract;
kidney; liver
Respiratory tract;
intestinal tract;
genitourinary tract;
liver, kidney,
neurons;
monocyte;
Tlymphocyte; and
histiocytic cell lines
Viral replication efficiencyHighHigher
Ability to inhibit IFN productionDelayed recognition and proinflammatory responseDelayed recognition and proinflammatory response
Table 2. The genomic characterization of SARS-CoV and MERS-CoV.
Table 2. The genomic characterization of SARS-CoV and MERS-CoV.
SARS-CoVMERS-CoV
Length of nucleotides29,72730,119
Open reading frames (ORFs)1111
Structural protein44
Spike protein (length of amino acids)12551353
S1 subunitReceptor-binding domain (RBD)318–510367–588
Receptor-binding motif (RBM)424–494484–567
S2 subunitHeptad repeat 1 (HR1) domains892–1013984–1104
Heptad repeat 2 (HR2) domains1145–11951246–1295
Non-structural proteins (NSPs)At least 516
Accessory proteins85
A characteristic gene order5′-replicase ORF1ab, spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3′
Table 3. Vaccine strategies of SARS-CoV and MERS-CoV.
Table 3. Vaccine strategies of SARS-CoV and MERS-CoV.
Vaccine StrategyProcess of ProductionReferencesAdvantagesDisadvantages
SARSMERS
Inactivated virus vaccinesVirus particles are inactivated by heat, chemicals, or radiationWhole virus, with or without adjuvant (promote an effective immune response against the inactivated pathogen) [93,94]Whole virus, with or without adjuvant (promote an effective immune response against the inactivated pathogen) [91,95]Maintained virus particles structure; rapidly develop; easy to prepare; safety; high-titer neutralizing antibodies [93]; protection with adjuvant [96,97].Potential inappropriate for highly immunosuppressed individuals; possible TH2 cell-distortive immune response [98,99].
Live-attenuated virus vaccinesAttenuated the virulence, but still keeping it viable by mutagenesis or targeted deletionsEnvelope protein deletion [100]; non-structural protein 14 (nsp14) and exonuclease (ExoN) inactivation [101]Full-length infectious cDNA clone or mutant viruses [102]Inexpensive; quick immunity; less adverse effect; activates all phases of the immune system [103]; more durable immunity; more targeted [77].Phenotypic or genotypic reversion possible; need sufficient viral replication [77].
Viral vector vaccinesGenetically engineered unrelated viral genome with deficient packaging elements for encoding targeted geneSpike and nucleocapsid proteins [100,104]Spike and nucleocapsid proteins [87,88]Safety; stronger and specific cellular and humoral immune responses [77].Varies inoculation routes may produce different immune responses [96]; possibly incomplete protection; may fail in aged vaccinees; possible TH2 cell-distortive immune response [105].
Subunit vaccinesAntigenic components inducing the immune system without introducing viral particles, whole or otherwise.Spike and nucleocapsid proteins [53,59,106]Spike and nucleocapsid proteins [85,86,107,108]High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies [109].Uncertain cost-effectiveness; relatively lower immunogenicity; need appropriate adjuvants [77].
DNA vaccinesGenetically engineered DNA for directly producing an antigenSpike and nucleocapsid proteins [110,111]Spike and nucleocapsid proteins [89,90]Easier to design; high safety; high-titer neutralizing antibodies [110].Lower immune responses; potential TH2 cell-distortive immune response results; potential ineffective; possibly delayed-type hypersensitivity [112].
Table 4. Potential therapeutics for severe acute respiratory syndrome (SARS) and MERS.
Table 4. Potential therapeutics for severe acute respiratory syndrome (SARS) and MERS.
TreatmentStage of Development
SARS (Notes)MERS (Notes)
Host protease inhibitorsEffective in mouse models [138]In vitro inhibition [138]
Viral protease inhibitorsIn vitro inhibition [139]In vitro inhibition [140]
Monoclonal and polyclonal antibodiesEffective in mouse, ferrets, golden Syrian hamster [124,141,142] and non-human primate models [143,144]Effective in mouse, rabbit, and non-human primate models [10,145]
Convalescent plasmaOff-label use in patients [146,147]Effective in a mouse model; clinical trial approved [10]
InterferonsOff-label use in patients (often in combination with immunoglobulins or thymosins) [146,147]Effective in non-human primate models; off-label use in patients (often in combination with a broad-spectrum antibiotic and oxygen) [10]
RibavirinOff-label use in patients (often in combination with corticosteroids) [146,147]Effective in a non-human primate model; off-label use in patients (often in combination with a broad-spectrum antibiotic and oxygen) [10]
Lopinavir and ritonavirOff-label use in patients (improved the outcome in combination with ribavirin) [146,147]Effective in a non-human primate model; off-label use in patients [10,148]
Common FeatureNone of these therapeutic agents are approved for commercial use in humans

Share and Cite

MDPI and ACS Style

Song, Z.; Xu, Y.; Bao, L.; Zhang, L.; Yu, P.; Qu, Y.; Zhu, H.; Zhao, W.; Han, Y.; Qin, C. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses 2019, 11, 59. https://0-doi-org.brum.beds.ac.uk/10.3390/v11010059

AMA Style

Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses. 2019; 11(1):59. https://0-doi-org.brum.beds.ac.uk/10.3390/v11010059

Chicago/Turabian Style

Song, Zhiqi, Yanfeng Xu, Linlin Bao, Ling Zhang, Pin Yu, Yajin Qu, Hua Zhu, Wenjie Zhao, Yunlin Han, and Chuan Qin. 2019. "From SARS to MERS, Thrusting Coronaviruses into the Spotlight" Viruses 11, no. 1: 59. https://0-doi-org.brum.beds.ac.uk/10.3390/v11010059

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop